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ABSTRACT
Lipoate is an essential cofactor of several proteins involved in cellular
energy homeostasis and catabolism. Lipoate metabolism has been linked to
pathogenesis in some microbial species, but its role in Staphylococcus aureus
infections had not been explored. In this thesis, we tested the hypothesis that
lipoate acquisition mechanisms promote S. aureus infectivity. We used a
bacterial genetics approach to elucidate the biological function of the S. aureus
genes involved in lipoate metabolism. Our findings allowed us to propose a
model for lipoic acid de novo biosynthesis and salvage pathways in S. aureus.
Moreover, we detail hitherto undescribed genetic arrangements of lipoate de
novo biosynthesis and salvage genes in the S. aureus genome, which suggest a
potential role for lipoate acquisition mechanisms in metabolic regulation and
oxidative stress defense. Also, we have identified critical requirements for gene
products involved in lipoate metabolism in murine sepsis. Our data indicate that
S. aureus is capable of using bacterial and host-derived lipoate during infection in
a tissue-specific manner, thereby promoting survival in diverse nutrient-restricted
environments. Overall, our findings suggest that the S. aureus lipoate de novo
biosynthesis and salvage pathways offer potential for the development of novel
therapeutics that target key metabolic programs in S. aureus.
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CHAPTER ONE
LITERATURE REVIEW
Introduction
Staphylococcus aureus is a commensal bacterium that can be found
colonizing the skin in humans. About a fifth of the human population are
permanently colonized with S. aureus and almost of 60% of humans are
occasional carriers (1-3). S. aureus is also a prominent pathogen capable of
invading several organs and tissues causing mild to severe, or even fatal
infections (2-4). Special concern has been raised in society over the increasing
number of patients infected with hypervirulent or antimicrobial-resistant S. aureus
strains, acquired by both immunocompromised patients at health-care facilities
and otherwise healthy individuals from community environments (5-8).
S. aureus has developed sophisticated strategies to survive in different
mammalian tissues, both as a commensal and as a pathogen. Upon infection, it
evades the host immune responses by secreting numerous virulence factors,
such as pore-forming toxins and proteases (3, 4). Moreover, this species readily
adapts to nutrient restriction to survive within the host; iron acquisition
mechanisms are a clear example of the remarkable ability of S. aureus to hunt for
nutrients (9, 10).
1	
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Lipoate is an essential cofactor in central metabolism in bacteria since it
enables the function of several proteins that lead to the production of cellular
energy and vital metabolites, such as amino acids and fatty acids (11, 12).
Interestingly, lipoate acquisition pathways have been linked to pathogenesis in
several bacterial and malarial species (13-18). For example, Listeria
monocytogenes, which is a Gram-positive pathogen that belongs to the same
taxonomic phylum as S. aureus, requires lipoate salvage to infect the host,
demonstrating that the mechanism for incorporating this cofactor could promote
pathogenesis in a wide range of bacteria (16, 19).
A deep understanding of the elements that promote S. aureus fitness and
prevalence during infection is a matter of paramount importance for the design of
new therapeutics against this pathogen. Lipoate metabolism in S. aureus is
poorly understood and the role of lipoate acquisition during infection is currently
unknown (16). Therefore, investigating S. aureus lipoate metabolism and its role
in pathogenesis could reveal novel targets for developing antimicrobial agents
against this major pathogen.
Staphylococcus aureus
S. aureus is a major human pathogen
Skin and soft tissue infections such as impetigo, folliculitis and cellulitis are
amongst the most common diseases caused by S. aureus (5, 7, 8, 20). This
pathogen can also cause respiratory diseases such as pneumonia and can
induce sepsis upon spread into the bloodstream (3, 21). Furthermore, S. aureus
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is the leading cause of infectious endocarditis in the United States and is often
associated with osteomyelitis in young children (22-25). Mortality and morbidity
due to staphylococcal infections constitute a significant economic burden for
society (5, 26, 27).
A variety of factors can increase the risk of infection in patients. These
include the use of foreign bodies such as catheters or prostheses, the presence
of underlying health conditions, as well as current or recent hospitalization. In
addition, treatment of S. aureus-derived diseases constitutes a current challenge
in public health due to the increasing antimicrobial resistant strains found in the
clinic (5, 8, 22, 27, 28).
According to the World Health Organization’s First Global Report on
Antibiotic Resistance (28), people infected with MRSA (methicillin-resistant S.
aureus) are estimated to be 64% more likely to die than those infected with nonresistant strains. A clear understanding of S. aureus pathogenesis could have a
significant socio-economic impact on the prevention and treatment of both
community-acquired and hospital-acquired infections (5, 7, 8, 29).
Numerous virulence factors contribute to S. aureus pathogenicity
The ability to infect and survive in a broad spectrum of host tissues makes
S. aureus a major pathogen. In order to cause disease, the bacterium has to
colonize the host while simultaneously evading and/or suppressing host immune
responses (6, 30). To counter these defense mechanisms and succeed at
infecting the host, S. aureus produces numerous virulence factors (1, 3, 6, 31).
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Among the arsenal of S. aureus virulence factors are several key surface
proteins (6, 32). These cell wall-anchored (CWA) proteins are attached to
peptidoglycan and mediate processes such as attachment to host cells,
disruption of immune responses or stimulation of biofilm formation (6, 33). For
example, the protein Clumping factor B is capable of binding fibrinogen and
molecules expressed by squamous cells, thus promoting attachment to the skin
surface (3). Another group of S. aureus CWA proteins, the iron-regulated surface
determinant (Isd) proteins, facilitate iron binding and uptake, and support survival
in iron-limiting environments including the skin and mucosa (31, 34). Expression
of several CWA proteins depends on growth conditions and S. aureus nutritional
status, highlighting their role in promoting adaptation to fluctuations in
environmental conditions (1, 3, 32). Another major CWA S. aureus virulence
factor is the deeply studied Protein A, which sequesters antibodies by binding
IgG molecules by the Fc region (6, 31, 35). This prevents proper recognition by
Fc receptors on phagocytic leukocytes interfering with phagocytosis and
activation of the complement cascade.
As highlighted by the function of the CWA Protein A, S. aureus is capable
of producing a wide variety of both cell wall linked and secreted factors that
protect against major host immune defenses including, but not limited to,
phagocytosis and complement activation. During infection with S. aureus, one of
the most important mechanisms used to combat the pathogen is
opsonophagocytosis and subsequent induction of the respiratory burst (30, 31,
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36). This process is initiated by migration of neutrophils to the site of infection, an
event that is mediated by a gradient of diffusible peptides derived from the
pathogen (i.e. N-formyl peptides) and the host, (i.e. complement degradation
products). Upon reaching the site of infection, neutrophils pass through the blood
vessel endothelium and migrate into the tissue. S. aureus interferes with these
processes by secreting inhibitory molecules that can block neutrophil adhesion
and migration (30, 31, 36). For example, S. aureus produces the staphylococcal
superantigen-like proteins -5 and 11, which compete with neutrophil cell
receptors and decrease neutrophil binding and rolling through the endothelium
(3, 37). Additionally, S. aureus is capable of inhibiting neutrophil migration to
infected tissues by secreting small proteins such as CHIPS, chemotaxis inhibitory
protein of staphylococci, and SCIN, Staphylococcal complement inhibitor, which
binds receptors on the membrane of neutrophils, preventing the process of
chemotaxis and allowing the bacterium to evade phagocytosis (38-40).
Although inhibiting phagocyte recruitment and complement activation are
key virulence strategies, S. aureus also employs other methods to evade the
respiratory burst initiated after phagocytosis. For example, S. aureus can detoxify
reactive oxygen species by producing enzymes such as catalase, superoxide
dismutase and a variety of other proteins with antioxidant properties (1, 3, 6, 35).
Secreted toxins also play a major role in the pathogenesis of S. aureus.
Most noteworthy are the myriad cytotoxic agents that can damage host cell
membranes. The membrane damaging α-toxin, also known as Hla or alpha	
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hemolysin, is one of the most studied virulence factors in S. aureus (40, 41). The
toxin binds to specific receptors on susceptible cells to induce lysis, releasing
cytosolic content that trigger a potent inflammatory reaction. Another group of
secreted proteins, named leukocidins, specifically target immune cells by forming
pores after oligomerization on the cell surface. The leucocidins include HlgAB,
HlgCB, LukAB/HG, LukMF, Panton-Valentine leucocidin (PVL), and LukED. This
wealth of bicomponent pore-forming proteins leads to a broad spectrum of
hemolytic, leukotoxic and dermonecrotic activities (23, 31, 42). Finally, phenolsoluble modulins are a group of small amphipathic cytolytic peptides produced by
S. aureus that can target white and red blood cells and promote inflammation in
the host (2, 3, 31, 42).
S. aureus enhances its pathogenicity through its ability to recover
essential nutrients from the site of infection. The scavenged compounds are then
used for all sorts of biochemical processes, from DNA synthesis to the production
of energy. Moreover, alterations in S. aureus nutrient-acquisition mechanisms
have been shown to affect its virulence (4, 10). The acquisition of transition
metals is a great example that demonstrates how S. aureus competes with the
host for essential nutrients (43). Mammalian cells have evolved mechanisms that
restrict iron availability, such as the intracellular location of iron and its
sequestration within iron-binding proteins, such as transferin, lactoferrin or
hemoproteins (34, 44). These strategies limit the proliferation of pathogens in a
defense process known as “nutritional immunity” (45). To circumvent this
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nutritional restriction, S. aureus has evolved mechanisms to release and
incorporate iron from host deposits, mainly from heme, which is the primary iron
reservoir in mammals. Proteins from the heme uptake systems extract
sequestered iron and the iron-chelators staphyloferrin A and B and aurochelin
facilitate the passage of this essential nutrient to the bacterial cytosol. These irondependent siderophores are upregulated in iron-deprived conditions (34, 44).
Interestingly, heme uptake systems, such as the Isd system, have been shown to
be essential for S. aureus pathogenesis by promoting trace metal acquisition that
leads to bacterial proliferation and persistence in the host (3, 10, 34, 43, 46).
A note on antimicrobial resistance
While the production of virulence factors is critical to S. aureus
pathogenesis, additional acquisition of a broad range of antibiotic resistance
genes has further augmented S. aureus pathogenicity and adverse outcomes
associated with failed treatment. Infections with antibiotic resistant bacterial
decrease the available tools to treat diseases and increase the patient's risk of
suffering from more severe complications. The prevalence and widespread
dissemination of antibiotic resistance genes has become a serious problem and a
major public health crisis. Meanwhile, very few novel therapeutic strategies are
being developed.
The extensive use of antibiotics both in the community, the clinic and in
the food industry has contributed to the selection of antimicrobial resistance
determinants in bacteria and promoted the emergence of pan-resistant species
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(47). Despite the role of the selective pressure derived from antibiotic utilization,
antimicrobial resistance in bacteria is a phenomenon rooted in complex genetic
mechanisms, including chromosomal alterations and trade of genetic information
among species (47, 48). (49).
For S. aureus, resistance to antimicrobials resides in its high adaptability
and mutability, which facilitate gene variations and the rapid incorporation of
extrachromosomal DNA (1, 5, 26). As a consequence of its multi-drug resistant
phenotype and its incidence worldwide, methicillin resistant S. aureus (MRSA)
has been widely studied (8, 20). Methicillin resistance in S. aureus occurred after
acquisition of a mobile genetic element known as the staphylococcal cassette
chromosome mec (SCCmec); SCCmec contains the mecA gene, which confers
resistance to penicillin drugs and β-lactam antibiotics, and it may carry additional
genes involved in resistance to other classes of antimicrobials and toxins, such
as the Panton-Valentine leucocidin (8, 50).
The rise of antibiotic resistance has not been restricted to methicillin since
a few S. aureus strains have begun to show reduced susceptibility to
antimicrobials commonly used to fight MRSA and infections caused by other
pathogens. Researchers hypothesize that intense use of the antibiotic
vancomycin as the therapeutic approach infections constituted a strong selective
pressure that fostered the acquisition of the vanA operon from vancomycinresistant enterococci (8, 47, 51). Additionally, resistance to non-β-lactam
antibiotics such as clindamycin has been detected in MRSA isolates from the
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community. This antibiotic resistance has been associated with the presence of
the pUSA03 plasmid containing the resistance genes ermA and ermC (5, 8)
The growing number of infections caused by multi-drug resistant and
highly virulent S. aureus strains isolated from community settings is a major
public health concern. Thus, further research on potential antimicrobial targets
and novel therapeutic approaches is required to reverse the increasing trend on
multi-drug resistance in S. aureus.
Final considerations
S. aureus is a fascinating and exceptionally successful pathogen. The
combined action of immunoevasion, immunosuppression, and nutrient
scavenging activities, in addition to its rapid acquisition of antibiotic resistance,
allow it to thrive in disadvantageous circumstances. In light of the information
provided in the literature, we can surmise that the outcome of a staphylococcal
infection is the result of a fine balance between the host immune responses and
the ability of the pathogen to subvert those defensive actions. On one side of the
spectrum, S. aureus infections can remain asymptomatic or localized due to
effective host defenses; on the other side lays the risk of bacterial dissemination
and disease due to bacterial counter-measures.
An increasing number of MRSA strains have begun to display complete or
partial resistance to previously effective drugs, reducing the spectra of available
effective antimicrobial drugs against this pathogen (5, 8, 50). The increased
frequency of infections caused by hyper virulent strains that show resistance to
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multiple antibiotics emphasizes the urgency of comprehensive studies on the
causes, severity and treatment of S. aureus infections.
Lipoate metabolism
Lipoate is required for metabolism and redox homeostasis
Lipoate is the deprotonated form of lipoic acid (Figure 1) (16). It is highly
conserved among species of different domains of life and acts as an essential
organosulfur cofactor in key multienzyme complexes that are involved in
oxidative and one-carbon metabolism (11). Lipoate itself and lipoylated
complexes are well conserved in nature, yet an important versatility exists among
organisms regarding their requirements for lipoate and its acquisition (11, 16).
Five multienzyme complexes depend on lipoate to function and these
have been extensively described in the literature: pyruvate dehydrogenase
complex (PDH); 2-Oxoglutarate dehydrogenase (OGDH); branched-chain 2Oxoacid dehydrogenase (BCODH); the glycine cleavage system (GCS) and
acetoin dehydrogenase complex (AoDH). Of note, all except one are encoded in
S. aureus genome; the AoDH is not synthesized or required for its metabolic
functions (11, 16).
The three 2- oxoacid dehydrogenases are composed of multiple copies of
three enzymatic subunits, E1, E2 and E3. The core of the complex contains the
E2 subunit bearing the lipoate molecule covalently attached to a well-conserved
lysine through an amide bond (Figure 1B) (16). Pyruvate dehydrogenase (PDH)
converts pyruvate to acetyl coenzyme A; 2-Oxoglutarate dehydrogenase (OGDH)
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is involved in the transformation of α-ketoglutarate into succinyl-CoA and the
branched-chain 2-Oxoacid dehydrogenase (BCODH) participates in the initial
steps of branched chain fatty acid synthesis (11, 16). The glycine cleavage
system (GCS) catalyzes the reversible decarboxylation of glycine and shows
differences in both sequence and structure compared to the 2- oxoacid
dehydrogenases. The GCS also contains a lipoate molecule attached to a
conserved lysine, but it is bound to the H subunit of this system (GcvH) (6). An
additional gene product related to the GCS has been found within the SirtM
operon of S. aureus, which encodes an ADP-ribosyltransferase and a noncanonical form of the Glycine cleavage complex H (gcvH-L) that appears to be
upregulated under conditions of redox stress (52, 53). Finally, the acetoin
dehydrogenase complex (AoDH), which is not present in S. aureus, also has
three catalytic subunits and is functionally related to PDH, but it does not
catalyze the oxidative decarboxylation of branched-chain 2-Oxoacids (16).
Despite their structural and functional differences, PDH, OGDH, BCODH
and GCS share an E3 subunit, which is responsible for recycling the disulfide
bond for a new catalytic cycle (11, 16). In these multienzyme complexes, the
lipoate molecule is responsible for binding substrates through its thioester bond,
where it tunnels those substrates between the active sites of the different
subunits (11). In addition to its role in catalysis, the disulfide bond formed by the
thiol groups is thought to be involved in redox reactions, conferring an important
role for lipoate as an antioxidant (11, 12, 16).
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A

B

Figure 1: Structure and function of the cofactor lipoate
A. The biologically active form of lipoic acid, lipoate. B. Reactions catalyzed by 2-Oxoacid
dehydrogenase complexes. First, the E1 subunit decarboxylates the 2- oxoacid substrate,
subsequently, the lipoyl cofactor on the E2 subunit transfers the acyl group to coenzyme A (CoA).
+

At the end of the cycle, lipoate is regenerated after reduction of NAD . Reprinted with permission
from Spalding and Prigge (Figure 16 - Appendix I)
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Lipoate can be scavenged or generated endogenously
Lipoylation is the posttranslational modification of proteins with lipoate,
and it can occur by two known mechanisms: via lipoate biosynthesis or through
lipoate scavenging from environmental sources (11). For those organisms that
can generate lipoate, de novo biosynthesis is catalyzed by the action of a lipoate
synthetase LipA, which uses octanoate, a molecule derived from fatty acid
metabolism, as a precursor (16, 54, 55). Lipoate scavenging, instead, involves
the acquisition of this cofactor from the environment and the direct ligation onto
proteins. This process is referred to as the salvage pathway and is catalyzed by
lipoate ligases (11, 15, 56).
Lipoate de novo biosynthesis occurs in two sequential steps, the transfer
of octanoate from an acyl carrier protein (ACP) to a protein subunit (generally a
member of one of the metabolic complexes described above), followed by the
insertion of two sulfur atoms into the octanoate backbone (11). The initial ligation
of octanoate to ACP depends on the enzymatic activity of the type II fatty acid
synthetase; the direct transfer of octanoate from ACP to a conserved lysine of
the target protein is catalyzed by an octanoyl transferase, which has been well
characterized in numerous species (11, 54, 57). Finally, LipA catalyzes the
irreversible conversion of the octanoyl group to a lipoate molecule by generating
a disulfide bond (11, 57).
Lipoate biosynthesis can be bypassed by the action of lipoate ligases,
which catalyze the insertion of free lipoate through generation of an amide bond
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directly to the E2/H subunit of the enzyme complexes (11). Since free lipoate is
rarely found to the environment due to its exclusive linkage to the protein
subunits of PDH, OGDH, BCODH, AoDH complexes, as well as GCS, free
lipoate has to first be made available by enzymes capable of breaking the lipoylprotein amide bond (11, 16). Free lipoate in vivo is believed to come mostly from
the gastrointestinal tract, where lipoate is released from lipoyl-proteins by the
action of an intestinal amidase. For bacterial pathogens, lipoate most likely
comes from damaged tissue, though it is not known whether or not all or some
bacterial species encode an analogous amidase or similar enzyme that releases
lipoate from source lipoyl-peptides (16). Of note, some ligases are also involved
in the salvage of octanoate, which means that they can incorporate octanoate
into target proteins, bypassing the action of the octanoyl transferase; yet, the use
of octanoate as an exogenous source necessitates that the bacterium have a
functional lipoate synthetase to generate lipoic acid (11, 16, 54).
Escherichia coli, Bacillus subtilis, and Listeria monocytogenes are three
bacteria whose lipoate biosynthesis and salvage pathways are well
characterized. In E. coli, de novo lipoate biosynthesis occurs after the sequential
action of an octanoyl transferase, LipB, and a lipoate synthetase, LipA, as
described above. The lipoate ligase, LplA, is capable of using both free lipoate
and octanoate to bypass this de novo biosynthesis pathway (58).
Figure 2

depicts B. subtilis pathways for protein lipoylation. Unlike E. coli,

the B. subtilis lipoate biosynthesis and salvage pathway requires four enzymes
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and is now considered the model pathway of bacterial lipoylation in Grampositive bacteria (11, 54, 59). Despite having a low degree of amino acid
sequence homology, B. subtilis LipM catalyzes the same reaction as E. coli LipB;
both are octanoyl transferases that remove an octanoate group exclusively from
an octanoyl-ACP and neither enzyme has ligase activity. In B. subtilis the
octanoyl group is transferred from the ACP to the H subunit of the GCS. This
observation is consistent with the hypothesis that GcvH is the first protein to be
lipoylated through the de novo biosynthesis in other microorganisms, such as
Plasmodium facilparum and Toxoplasma gondii (14, 59, 60). In addition to LipA
and LipM, the B. subtilis genome encodes a lipoate ligase, LplJ, and the
amidotransferase, LipL, capable of transferring both lipoate and octanoate (11,
59).
The food-borne human pathogen L. monocytogenes is a lipoate
auxotroph; it does not have a LipM or LipA homologs, thus, it has no means to
generate lipoate endogenously (16, 61). Nevertheless, this Gram-positive
bacterium has retained an amidotransferase enzyme, LipL and has two lipoate
ligases, LplA1 and LplA2 (16, 61). Remarkably, whole cell extracts of L.
monocytogenes have shown to have amidase activity, which facilitates the
release of lipoate from mammalian tissues followed by incorporation into E2 and
H subunits via the ligase LplA2 (15, 61).
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Figure 2: B. subtilis lipoylation mechanisms
This is the model lipoate biosynthesis pathway for B. subtilis (modified from Spalding et al.
Reprinted with permission from Spalding and Prigge (Figure 16 - Appendix I). Lipoate de novo
biosynthesis initiates with the transfer of an octanoyl group from an acyl carrier protein (ACP) to a
metabolic complex protein subunit (Octanoyl-E2) by the octanoyl transferase LipM. Subsequently,
the lipoate synthetase LipA catalyzes the irreversible conversion of octanoate to lipoate (LipoylE2). LipL is involved in transferring lipoate groups among different subunits of the lipoylated
enzyme complexes (Lipoyl-P2). Through the lipoate salvage pathway free lipoate is directly
bound to the protein subunit through the action of the lipoate ligase, LplJ (16, 54, 59).

Mechanisms of lipoate acquisition vary among microbial species
Phylogeny and functional analysis of the enzymes involved in lipoate
acquisition have revealed an interesting genetic diversity among species, even
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within the same phylum. In 2010, M.D. Spalding and S.T. Prigge surveyed the
literature on lipoic acid metabolism in bacterial, fungal, and protozoan
microorganisms and described the remarkable degree of diversity that exists
among microbial species (16). For example, the review indicates that some
species lack the enzymatic machinery to produce lipoate endogenously, while
others cannot scavenge lipoate or do not require lipoate to support survival at all.
Furthermore, not all species express the five known lipoylated enzyme
complexes, highlighting the diversity of lipoate acquisition and its metabolic
enzyme complexes in nature (11, 16, 61).
A comparison between Pseudomonas aeruginosa and Helicobacter pylori
highlights the diversity of lipoylation strategies found in Gram-negative bacteria.
H. pylori does not require lipoate enzymes to sustain growth. The bacterium
maintains an active TCA cycle by replacing the requirement of lipoic acidcontaining enzymes, KDH and PDH, with the alternate 2-Oxoglutarate
oxidoreductase (KOR) and the pyruvate:flavodoxin oxidoreductase (POR) (16).
In contrast, P. aeruginosa uses both the salvage and the biosynthesis pathway to
incorporate lipoate to five lipoylated enzyme complexes required for metabolic
efficiency (16).
Mycobacterium tuberculosis, Mycobacterium leprae and Corynebacterium
diphtheriae are three species of Actinobacteria that appear to depend exclusively
on the endogenous synthesis of lipoate, as they do not encode lipoate ligases.
These species have a lipoate metabolic pathway that resembles that of Gram	
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negative bacteria, although they lack of a KDH complex, whose function is
replaced by a 2-Oxoglutarate decarboxylase (16).
Gram-positive bacteria belonging to the phyla Firmicutes display additional
diversity in their lipoate utilization strategies. Some Clostridia species are lipoate
auxotrophs and encode a single lipoate ligase, while the major pathogenic
species within the order Bacillales can encode multiple lipoate ligases, a lipoate
synthetase, or both (16). For example, L. monocytogenes is a lipoate auxotroph
that encodes two lipoate ligases, LplA1 and LplA2 (61). Interestingly, these
lipoate ligases use different lipoylated substrates to replicate and have discrete
biological roles in vivo and in vitro (15, 19). B. subtilis encodes one lipoate ligase,
LplJ and has a complete set of enzymes dedicated to de novo biosynthesis
pathway (54, 59). The lipoic acid biosynthesis and salvage pathways of S.
aureus are currently unknown, but this species seems to encode a lipoate
synthetase and several lipoate ligases (16). Additionally, L. monocytogenes, B.
subtilis and S. aureus have different sets of lipoylated enzyme complexes; B.
subtilis codes for PDH, OGDH, BCODH, GCS and AoDH; S. aureus lacks AoDH
but encodes two GcvH proteins and L. monocytogenes lacks both KDH and
AoDH (16).
Protein lipoylation in yeasts is restricted to the mitochondria. These
microorganisms encode only three lipoylated enzyme complexes, PDH, KDH and
GCS and three enzymes involved in lipoate metabolism, Lip2, Lip3 and Lip5.
Saccharomyces cerevisiae and Candida albicans have the functional enzymatic
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machineries to generate lipoate endogenously (Lip2 and Lip3 are E. coli LipB
and LipA orthologs, respectively), but cannot scavenge lipoate despite encoding
a lipoate synthetase (Lip3). Interestingly, Lip3 is an amidotransferase involved in
transporting lipoyl groups from GCS to PDH and KDH. Thus, Lip2 and Lip5 are
required to lipoylate GCS and Lip3 confers the ability to lipoylate the additional
enzyme complexes found in the mitochondria (16).
In the pathogenic protozoans Plasmodium falciparum and Toxoplasma
gondii, lipoate is attached to the E2 subunits of PDH, OGDH, BCODH and the H
subunit of GCS, resembling the enzyme complexes found in Gram-positive
bacteria (13, 14, 18). Interestingly, the lipoylated complexes have different
subcellular location inside these parasites; PDH is located in the apicoplast and
GCS and BCODH are present in the mitochondrion (16, 60). Furthermore,
protein lipoylation differs in each organelle, with lipoate biosynthesis occurring in
the apicoplast and lipoate salvage occurring in the mitochondrion (17, 62). In
addition, malarial parasites encode LipA and LipB orthologs and two lipoate
ligases (14). As in L. monocytogenes, P. falciparum lipoate ligases have
substrate specificity; lipL1 preferentially lipoylates OGDH and PflipL2 catalyzes
the lipoylation of PDH (16).
In summary, lipoate is a conserved molecule that permits the function of
well-conserved enzyme complexes. Importantly, microbial species display a
remarkable diversity regarding lipoylation strategies, highlighting the role of
lipoate metabolism in adaptation to a variety of environmental niches.
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To date, the S. aureus lipoate biosynthesis and salvage pathways have not been
elucidated. Sequence alignment analyses suggest that this pathogen encodes a
lipoate synthetase ortholog and several lipoate ligases, but no octanoyl
transferase seems to be present in its genome. However, attempts to predict
functions based exclusively on amino acid homology in other species have led to
mistaken annotations and thus, the enzymatic activity of these putative lipoate
ligases deserves further investigation (6, 15).
Lipoate biosynthesis and salvage in microbial pathogenesis
Intuitively, the fundamental role of lipoate in catalysis and redox reactions
might have important implications for microbial pathogens, which often face
nutritional restrictions and reactive oxygen intermediates during host infection.
When considering microbial pathogenesis, the mechanisms of lipoate acquisition
have been found to promote survival and adaptation in different pathogens, from
bacteria to parasites and fungal species (11, 16). For example, it has been
shown that PDH mediates expression of T3SS in P. aeruginosa by stabilizing the
bacterial metabolic status through the production of acetyl-CoA (63). Additionally,
it has been established that the disruption of a lipoylated complex in M.
tuberculosis leads to increased susceptibility to macrophage killing and reduces
its pathogenicity (64). Finally, evidence suggests that lipoate scavenging in the
malarial parasite P. falciparum is required to infect the host (13, 16-18, 62).
The distinct roles that L. monocytogenes lipoate ligases, LplA1 and LplA2,
have in vivo and in vitro constitute a remarkable example of adaptation to nutrient
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deprivation during infection (61). One of its lipoate ligases, LplA1 has evolved to
function during infection, sequestering lipoate from the host. Interestingly, this
enzyme is dispensable in culture media (15, 61). Moreover, LplA1 and LplA2 are
capable of using alternative sources of lipoate, an effect that is facilitated by a yet
to be identified amidase present in whole cell lysates, which allows this pathogen
to take better advantage of restricted nutrients that are not immediately
bioavailable within the host (15, 59).
L. monocytogenes lipoate metabolism has also been topic of interest in
the context of protein secretion since the E2 PDH and GcvH subunits have been
found associated with the external bacterial surface. It is thought that these
proteins are secreted by an accessory secretion system in L. monocytogenes,
SecA2, which is required for virulence (16, 65). Although is currently unknown if
these E2 and H subunits are being actively secreted to support pathogenesis,
this raises the possibility that lipoylated proteins have a secondary function,
dissimilar from its original metabolic role, in what is referred to as a moonlighting
capacity (16, 65).
Having alternative lipoate acquisition mechanisms that enable lipoate
scavenging from resource-deprived contexts constitutes an important asset for
bacterial pathogens, beyond that of conferring metabolic adaptability. As stated
above, lipoate can confer antioxidant protection by quenching free radicals that
can ultimately kill bacterial cells. It does so by forming a redox couple with its
reduced form, the molecule dihydrolipoate. The dihydrolipoate-lipoate pair is
	
  

22
capable of neutralizing superoxide radicals, the hydroxyl radical and hydrogen
peroxide, as well as interacting with other antioxidants present in the cell
membrane and the cytosol (6, 17, 18).
Concluding remarks
As described above, S. aureus is a versatile bacterium that produces
myriad virulence factors in order to support colonization, tissue damage and
dissemination in the host. Moreover, S. aureus has an astonishing capacity to
adapt to different nutritional conditions as shown by its ability to scavenge
essential nutrients, such as iron (43, 44). Unraveling the existing mechanisms
behind S. aureus infection strategies is of paramount importance to develop new
therapeutic strategies with the potential to reduce the morbidity and mortality
associated with clinical disease. This thesis aims to study the role of one
essential nutrient, lipoate, to determine its contribution to S. aureus fitness and
pathogenesis.
The intersection of lipoate metabolism and virulence was first delineated
by the discoveries that linked lipoate acquisition to bacterial and malarial
pathogenesis, as shown for L. monocytogenes, T. gondii and P. falciparum (14,
15, 19, 62). The association of lipoate acquisition with microbial infection might
be based on the fundamental role that this cofactor has in aerobic metabolism
and redox homeostasis or may extend to additional moonlighting functions as
suggested in L. monocytogenes. At this point, our knowledge of the underlying
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processes that support this connection is minimal, in part due to the vast diversity
of lipoate acquisition mechanisms that exist among species.
It is somewhat surprising that lipoate metabolism and its role in
pathogenesis have not yet been explored in S. aureus, despite being one of the
most important human pathogens. Homology-based studies revealed that S.
aureus has a putative lipoate synthetase and several putative salvage ligases,
indicating that this pathogen is capable of both lipoate biosynthesis and
scavenging (16). The potential capacity to synthesize lipoate in addition to the
unusual number of putative lipoate ligases predicted in the S. aureus genome
open the question of whether this pathogen is capable of using different protein
lipoylation approaches during infection.
Important human pathogens have been shown to use alternative sources
of lipoate within the host (15, 61, 65) or compartmentalize the lipoylation
mechanisms in their cells, relying on lipoate biosynthesis to lipoylate proteins in
one organelle and supporting lipoylation through scavenging in another (14, 17,
18). Thus, it is conceivable that S. aureus has evolved alternative strategies to
incorporate this essential nutrient in different environments; For example, it may
use lipoate to adapt as a commensal bacterium and survive as an invasive
pathogen or to colonize a specific tissue and survive inside phagocytes.
An especially intriguing connection drawn by Rack et al. is the potential
relationship between protein lipoylation and oxidative stress responses, as well
as the potential role of lipoate in the regulation of essential metabolic processes
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in S. aureus (53). Furthermore, the existing evidence supporting the role of free
lipoic acid as a redox modulator could have implications in pathogenesis, as this
cofactor by itself could be used by S. aureus as a biological tool to cope with
oxidative stress caused by the host defenses.
The answer to many of these questions, especially the role of lipoate in S.
aureus pathogenesis, is hampered by our lack of knowledge on the mechanisms
that this pathogen uses to lipoylate proteins. The scope of this work is to
characterize the lipoate biosynthesis and salvage pathway in S. aureus and to
establish whether the acquisition of this cofactor has a role in its pathogenesis.

	
  

	
  

CHAPTER TWO
MATERIALS AND METHODS
Bacterial strains and culture conditions
All bacterial strains used in this study are listed in Table 1. S. aureus pulse
field gel electrophoresis type USA300 isolate LAC cured of its plasmids was used
as the parental (wild type) strain for all genetic manipulations. S. aureus
NCTC8325 derivative RN4220, S. aureus RN9011, E. coli DH5α and DC10B
were used as host strains for propagation of recombinant plasmids and plasmid
integration.
All E. coli strains were grown in Lysogeny Broth (LB) (Amresco)
supplemented with antibiotics as indicated below. For replication of S. aureus
strains, Tryptic Soy Broth (TSB) (Criterion) was used as a frich medium, and
Roswell Park Memorial Institute 1640 medium (RPMI) (Corning) supplemented
with 1% casamino acids (Amresco) was used as a defined medium lacking
lipoate and octanoate. Unless otherwise specified, cultures were incubated at
37°C in a shaking incubator at 200 rpm with tubes held at a 45° angle. When
required, LB and TSB media were solidified using 1.5% Agar (Amresco).
Where necessary, media were supplemented with the following antibiotics
or chemicals at the following final concentrations: ampicillin (AMP) at 100 µg/ml,
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Table 1: List of strains used in this study
Strain
USA300
LAC
DH5α
RN4220
RN9011
FA-S831
FA-S842
FA-S841
FA-S837
FA-S1176
FA-S1182
FA-S1249
FA-S1180
FA-S977
FA-S912
FA-S1251
FA-S957
FA-S994
FA-S1210
FA-S998
FA-S1178
FA-S992
FA-S1038
FA-S1041
FA-S1042
FA-S877
FA-S1119
FA-S1190
FA-S1258
FA-S1257
FA-S1206
FA-S1208
FA-S1259
FA-S1205
FA-S1260
FA-S1222
FA-S1200
FA-S1212

Genotype
S. aureus USA300 Strain LAC. Plasmid cured.

Designation
LAC (WT)

E. coli strain for recombinant pIMAY and pJC plasmids
Restriction deficient S. aureus for plasmid passage
RN4220 + pRN7203 expressing SaPI integrase
AH-LAC with an in-frame deletion of lipA
AH-LAC with an in-frame deletion of lipM
AH-LAC with an in-frame deletion of lplA1
AH-LAC with an in-frame deletion of lplA2
AH-LAC with an in-frame deletion of lipL
AH-LAC with in-frame deletions of lipA and lipM
AH-LAC with in-frame deletions of lipA and lplA1
AH-LAC with in-frame deletions of lipA and lplA2
AH-LAC with in-frame deletion of lipA and ΔlipL:kan
AH-LAC with in-frame deletions of lplA1 and lplA2
AH-LAC with in-frame deletions of lipM and lplA1
AH-LAC with in-frame deletion of lipM and transposon
insertion in lplA2 transduced from NE266 (lipM:erm)
AH-LAC with in-frame deletion of lipM and ΔlipL:kan
AH-LAC with in-frame deletions of lipL and lplA1
AH-LAC with in-frame deletions of lplA2 and ΔlipL:kan
AH-LAC with in-frame deletions of lipA, lplA1, and lplA2
AH-LAC with in-frame deletion of lipA, ΔlipL:kan, and
transposon insertion in lipM transduced from NE1334
AH-LAC with in-frame deletion of gcvH
AH-LAC with in-frame deletion of E2-PDH
AH-LAC with in-frame deletion of E2-OGDH
FA-S831 complemented with pJC1112-lipA
FA-S842 complemented with pJC1111-lipM
FA-S1176 complemented with pJC1111-lipL
FA-S1176 complemented with pJC1111-pta
FA-S1176 complemented with pJC1111-pta-lipL
FA-S912 complemented with pJC1111-lplA1
FA-S912 complemented with pJC1111-lplA2
FA-S1249 complemented with pJC1111-lplA1
FA-S1180 complemented with pJC1111-lplA2
FA-S1251 complemented with pJC1111-lplA1
FA-S1182 complemented with pJC1111-lipM
FA-S1178 complemented with pJC1111-lplA1
FA-S1178 complemented with pJC1111-lplA2

RN4220
RN9011
ΔlipA
ΔlipM
ΔlplA1
ΔlplA2
ΔlipL
ΔlipAΔlipM
ΔlipAΔlplA1
ΔlipAΔlplA2
ΔlipAΔlipL
ΔlplA1ΔlplA2
ΔlipMΔlplA1
ΔlipMΔlplA2
(ΔlipM-lplA2::erm)
ΔlipMΔlipL
ΔlipLΔlplA1
ΔlipLΔlplA2
ΔlipAΔlplA1ΔlplA2
ΔlipLΔlipAΔlipM
(Δlip-LΔlipA-lipM::erm)
ΔgcvH
ΔE2-PDH
ΔE2-OGDH
ΔlipA+lipA
ΔlipM+lipM
ΔlipL+lipL
ΔlipL+pta
ΔlipL+pta-lipL
ΔlplA1ΔlplA2+lplA1
ΔlplA1ΔlplA2+lplA2
ΔlipAΔlplA1+lplA1
ΔlipAΔlplA2+lplA2
ΔlipMΔlplA1+lplA1
ΔlipAΔlipM+lipM
ΔlipAΔlplA1ΔlplA2+lplA1
ΔlipAΔlplA1ΔlplA2+lplA2

The mutant strains listed in this table were generated with the help of former and current members
of the lab under supervision of Dr. Francis Alonzo: Azul Zorzoli (~40% of the mutant strains), Ryan
Novak, James Grayczyk and Irina Laczkovich.
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erythromycin (ERM) at 3 µg/ml, kanamycin (KAN) at 50 µg/ml, neomycin (NEO)
at 50 µg/ml, chloramphenicol (CM) at 10 µg/ml (Amresco), anhydrous
tetracycline (ANTET) (Acròs Organics) at 1 µg/ml, CdCl2 (Alfa Aesar) 0.3mM, Na
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Citrate (Sigma) 10mM. Media used for experiments in which the requirement for
lipoate or octanoate had to be bypassed were supplemented with the following
short branched-chain carboxylic acids (Sigma): 10.8 mM isobutyric acid, 9.2 mM
2-methylbutyrate and 9 mM isovalerate, and 10 mM sodium acetate (Sigma).
This medium has been previously used to bypass the metabolic requirement for
lipoylated enzyme complexes involved in TCA cycle and branched chain amino
acid catabolism (54) and will be referred as +BCFA throughout this document.
Molecular genetic techniques
S. aureus chromosomal DNA was isolated using Wizard Genomic DNA
purification kit following the manufactures protocol (Promega). A 2 mg/ml stock
solution of lysostaphin (Ambi Products, NY) was stored at -80°C in 20 mM
sodium acetate, pH 4.5. For genomic DNA isolation, 2.5ul of the stock solution
was added to a 1.2 mL culture of S. aureus that had been pelleted by
centrifugation and resuspended in 200 ul of TSM buffer (50mM Tris, 0.5M DSucrose,10 mM MgCl2 pH 7.5), followed by incubation for 15 minutes at 37°C to
digest the cell wall. After lysostaphin treatment, the bacteria were centrifuged at
maximum speed for 3 minutes in a microcentrifuge and bacterial DNA extracted
following the remainder of the manufacturer’s protocol. QIAGEN Mini / Midi
plasmid isolation kits were used to extract recombinant plasmids. DNA gel
extraction was performed using QIAGEN QIAquick kit. Polymerase chain
reaction (PCR) was performed in Flexid Mastercycler (eppendorf) using Phusion
High-Fidelity DNA Polymerase (New England Biolabs), oligonucleotides from
	
  

28
Eurofins and dNTPs from Quanta Biosciences. DNA ligation was performed in
eppendorf ThermoMixer C using T4 DNA ligase (New England Biolabs). PCR
purification was done using a QIAquick kit from QIAGEN. Genscript performed
sequencing. All restriction endonucleases were purchased from New England
Biolabs. 0.8% agarose gels (Amresco) was used for DNA electrophoresis.
E. coli competent cells preparation
A 3 mL culture of E. coli was grown overnight at 37°C in a shaking
incubator. The following day, the strain was subcultured at a 1:55 dilution (2 mL
into 110 mL) of LB in a 250 mL flask. Bacteria were incubated at 37°C with
shaking for ~2.5 hr until reaching mid-logarithmic phase (OD600 0.3 -0.4). All
remaining steps were conducted using pre-chilled solutions, flasks, and tubes.
Four 50 mL tubes containing 25 mL of the log-phase culture were kept on ice for
a period of 10 min, after which they were centrifuged at 4,000 rpm for 10 min at
4°C. Bacterial cells were harvested after decanting the supernatant and washed
twice in 10 mL of filter-sterilized Transformation Buffer 1 (TBF-1) (30 mM KOAc,
100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 15% Glycerol, adjusted at pH 5.8
with 0.2 M Acetic Acid). Cells were incubated on ice for 10 minutes between
washes. After a final centrifugation step at 4,700 rpm for 5 min the bacterial pellet
was suspended in 1 mL of filter-sterilized Transformation Buffer 2 (TBF-2) (10
mM MOPS, 10 mM RbCl2, 75 mM CaCl2, 15% Glycerol (Amresco), adjusted at
pH 6.5 with KOH). Finally, 100 µL of the competent cells were immediately
aliquoted into 1.5 mL microcentrifuge tubes and stored at -80°C.
	
  

29
E. coli heat transformation
In order to transform chemically competent E. coli, 2 µL of the ligation
product or purified plasmid was incubated with 50 µL competent cells on ice for
20 min. Afterwards, cells were incubated at 42°C for 45 seconds, placed on ice
for 2 min and then suspended in 250 µL of SOC medium. (tryptone (Amresco),
0.5 % yeast extract (Amresco), 0.05 % NaCl (Amresco) in distilled water,
supplemented with 10% 250mM KCl (Amresco) and adjusted to a pH 7.0 using
5M NaOH (Amresco). After autoclaving and cooling, 20% filter-sterilized 1M
glucose solution was added. Incubation was performed with shaking at 30°C for
1 hr, after which 100 µL of the culture was spread onto LB selection plates
containing the required antibiotic supplements.
Preparation of S. aureus electrocompetent cells
S. aureus competent cells were prepared by inoculating 300 µL of an
overnight culture into 30 mL of fresh TSB. Cells were incubated with shaking at
37°C for 3 hr until reaching mid-logarithmic stage followed by centrifugation at
8,000 rpm for 10 min at 4°C. Unless indicated, cells were kept on ice throughout
the entire process and all solutions and tubes used were pre-chilled. The
bacterial pellet was washed 2 times in 30 mL ice-cold 10% glycerol. Cells were
then resuspended in 15 mL 10% glycerol followed by additional centrifugation at
8,000 RPM for 10 min to pellet the bacteria. Lastly, cells were resuspended in 3
mL 10% glycerol and 200-500 µL aliquots were distributed into microcentrifuge
tubes and stored at -80°C. Strains that harbored antibiotic resistance cassettes
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were grown in media supplemented with antibiotics. Strains that showed
impaired growth due to lipoate biosynthesis defects were grown in BCFA media.
S. aureus transformation via electroporation
Transformation was performed by incubating a mixture of 50 µL of thawed
S. aureus competent cells with 10 µL of purified plasmid (~1 µg) at room
temperature for 30 min. Cells were transferred to a 2 mm electroporation cuvette
(VWR) and pulsed at 1,800 V, 10 µF, and 600 Ω in a GenePulser Xcell BIORAD
electroporator. Cells were recovered using TSB or TSB+BCFA as needed,
transferred to a microcentrifuge tube and incubated for 1 hr and 30 min.
Afterwards, 100 µL were spread onto TSA plates supplemented with the
appropriate antibiotics and incubated at 30°C for 24-48 hr.
Construction of mutagenesis vectors
Two fragments corresponding to ~500 nucleotides upstream (us) of the
start codon (ATG) and ~500 nucleotides downstream (ds) from the stop codon
(TAA) of the target gene of interest were amplified using oligonucleotide pairs
shown in Table 2. Specifically, each us fragment was PCR amplified from wild
type S. aureus genomic DNA using oligonucleotide #1 and oligonucleotide #2. ds
fragments were generated using oligonucleotide #3 and oligonucleotide #4
(Table 2). Both us and ds amplicons were purified and used as templates in a
SOEing PCR reaction to obtain the final amplicon required for mutagenesis.
Each amplicon of ~1000 nucleotides was subcloned into pIMAY using KpnI and
SacI restriction endonucleases.
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Table 2: List of oligonucleotides used in this study
Name
0829SOE1-Kpn
0829SOE2-Kas
0829SOE3-Kas
0829SOE4-Sac
0930SOE1-Kpn
0930SOE2-Kas
0930SOE3-Kas
0930SOE4-Sac
0328SOE1-Kpn
0328SOE2-Kas
0328SOE3-Kas
0328SOE4-Sac
1494SOE1-Kpn
1494SOE2-Kas
1494SOE3-Kas
1494SOE4-Sac
0571SOE1-Kpn
0571SOE2-Kas
0571SOE3-Kas
0571SOE4-Sac
0791SOE1-Kpn
0791SOE2-Kas
0791SOE3-Kas
0791SOE4-Sac
0995SOE1-Kpn
0995SOE2-Kas
0995SOE3-Kas
0995SOE4-Sac
1305SOE1-Kpn
1305SOE2-Kas
1305SOE3-Kas
1305SOE4-Sac
1464SOE1-Kpn
1464SOE2-Kas
1464SOE3-Kas
1464SOE4-Sac
KanF-Kas
KanR-Kas
0829CompF-Bam
0829CompR-EcoRI
UniCompSOE1-Pst
0328CompSOE2
0328CompSOE3
0328CompSOE4-Sac
0930CompSOE2
0930CompSOE3
0930CompSOE4-Sac
1494CompSOE2
1494CompSOE3
1494CompSOE4-Sac
0571CompSOE2
0571CompSOE3
0571CompSOE4-Sac
ptaSOE1-Pst
ptaSOE2
ptaSOE3
ptsSOE4
pta-0571SOE1-Pst
pta-0571SOE2
pta-0571SOE3
pta0571SOE4-Sac

1!

Ref
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
1
2
3
4
2
1
4
1
2
3
4
1
2
3
4

C1
C2
C3
C4
C2
C3
C4
C2
C3
C4
C2
C3
C4
C1
C2
C3
C4
C1
C2
C3
C4

Sequence
CCC-GGTACC(KpnI)-GCACAATGTGCCATCATCAA
CCTTATTAATGGTTAAATATTAACT-GGCGCC(KasI)-CGCCATAACAACACATACCC
GGGTATGTGTTGTTATGGCG-GGCGCC(KasI)-AGTTAATATTTAACCATTAATAAGG
CCC-GAGCTC(SacI)-ATTAATGTTCAGTATCTTGAATG
CCC-GGTACC(KpnI)-GCATTATACCTGTATAAATAC
ATAGTCCTTTAATCGTTTATGA-GGCGCC(KasI)-TTTCATTACAATCTCTCCCTT
AAGGGAGAGATTGTAATGAAA-GGCGCC(KasI)-TCATAAACGATTAAAGGACTAT
CCC-GAGCTC(SacI)-ATAAGCAAAACCTCGCTTTAT
CCC-GGTACC(Kpn1)-TATTTCATATACAAGGGGAGTATA
CATACATAAAATAACAATATTAACT-GGCGCC(KasI)-GTACATCTTCTGTCTCTCCA
TGGAGAGACAGAAGATGTAC-GGCGCC(KasI)-AGTTAATATTGTTATTTTATGTATG
CCC-GAGCTC(SacI)-CTTGTGATAAATCCGCTTCG
CCC-GGTACC(KpnI)-TTATAGCCGCCTTTTAACATA
CATTTTTTATTCTAAAAACTACTT-GGCGCC(KasI)-AGTCATATTCAAGAACTCCTA
TAGGAGTTCTTGAATATGACT-GGCGCC(KasI)-AAGTAGTTTTTAGAATAAAAAATG
CCC-GAGCTC(SacI)-ATATTCAAAGTGCTCACACTT
CCC-GGTACC(KpnI)-AAGTGCAAAATCAGCATTAAG
GGCTGTTAAATATTTAACTATTG-GGCGCC(KasI)-TTGCATAGGTTCTAATCCAG
CTGGATTAGAACCTATGCAA-GGCGCC(KasI)-CAATAGTTAAATATTTAACAGCC
CCC-GAGCTC(SacI)-GTTGCATACGCATTCTCGT
CCC-GGTACC(KpnI)-AGGTTGCAGTCGTATGATTA
ATTAAGGAGTTACACGGTGA-GGCGCC(KasI)-GAGAATCCCCTCCTAATTAA
TTAATTAGGAGGGGATTCTC-GGCGCC(KasI)-TCACCGTGTAACTCCTTAAT
CCC-GAGCTC(SacI)-CAGACATTCCATACATTTGATC
CCC-GGTACC(KpnI)-TGAAGAAGTACCTGAAGAAG
GAAATCTCCAACTACCATGTT-GGCGCC(KasI)-GTTTTTGCCCTCCTAAGATT
AATCTTAGGAGGGCAAAAAC-GGCGCC(KasI)-AACATGGTAGTTGGAGATTTC
CCC-GAGCTC(SacI)-TACTTCTTGTAAGTTTAAAGCA
CCC-GGTACC(KpnI)-TGCACAAGCGGCTAGTTTA
TAAACTATTTTGTGTTGTGGA-GGCGCC(KasI)-GACTTATTTCCCCCTAGTTA
TAACTAGGGGGAAATAAGTC-GGCGCC(KasI)-TCCACAACACAAAATAGTTTA
CCC-GAGCTC(SacI)-AATCATAAATTATAGAATATCGG
CCC-GGTACC(KpnI)-GCTAAAGGGCTTTTATTATCA
ATAGATGCATCTATGTTATCA-GGCGCC(KasI)-ACTTTCCCTCCCTAGAATT
AATTCTAGGGAGGGAAAGT-GGCGCC(KasI)-TGATAACATAGATGCATCTAT
CCC-GAGCTC(SacI)-GCTGGTCTTGCGATACCA
TCCC-GGCGCC(KasI)-CTCGACGATAAACCCAGCGAAC
TCCC-GGCGCC(KasI)-CTTTTTAGACATCTAAATCTAGGTAC
GGC-GGATCC(BamHI)-GTAAGATTATTGGATTTTCATTT
GGC-GAATTC(EcoRI)-CTATCTATGACAATGAAAGG
ATAT-CTGCAG(PstI)-ATCCCATTATGCTTTGGCA
AATCGGTTCTATTAAGTACATGGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCCATGTACTTAATAGAACCGATT
ATAT-GAGCTC(SacI)-TAGAAACAAAAACCATATATATA
ATTATTATTACTAATGAATTTCATGGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCCATGAAATTCATTAGTAATAATAAT
ATAT-GAGCTC(SacI)-ACTATTCTTAACATCTCATAC
AAAATTCCAAGTTTCAGTCATGGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCCATGACTGAAACTTGGAATTTT
ATAT-GAGCTC(SacI)-TGTAGGTAAAATAGTCTACG
CGAATGCGAAAGATTGCATGGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCCATGCAATCTTTCGCATTCG
ATAT-GAGCTC(SacI)-AAAAATAACAGCCCCAAACG
ATAT-CTGCAG(PstI)-ATCCCATTATGCTTTGGCA
ATACATTTAATAAATCAGCCATGGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCCATGGCTGATTTATTAAATGTAT
ATAT-GAGCTC(SacI)-TTATTGTAAGGCTTGCGCT
ATAT-CTGCAG(PstI)-ATCCCATTATGCTTTGGCA
ATACATTTAATAAATCAGCCATGGGTTTCACTCTCCTTCTA
TAGAAGGAGAGTGAAACCCATGGCTGATTTATTAAATGTAT
ATAT-GAGCTC(SacI)-AAAAATAACAGCCCCAAACG
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Generation of in-frame deletion mutants
Briefly, recombinant pIMAY containing 500 bp regions of homology us and
ds of the target gene were transformed into S. aureus LAC via electroporation
and propagated at 28-30°C in the presence of chloramphenicol. Plasmid
recombination into the chromosome was induced by shifting to 37°C, a nonpermissive temperature for pIMAY replication, in the presence of
chloramphenicol. Plasmid integrants were then incubated at 30°C without
antibiotics, to induce plasmid replication and excision from the chromosome.
Bacteria were subsequently plated on medium containing anhydrous tetracycline
(AnTet), which induces the expression of a secY antisense RNA transcript under
control of the Pxyl/tetO promoter and serves as an effective counter-selection
against any S. aureus still harboring pIMAY. Following counter-selection,
chloramphenicol sensitive bacteria were screened for the presence of the desired
mutation by PCR.
Construction of marked deletion mutants
To overcome difficulties encountered when generating mutants with
growth deficiencies (lipL, e2-pdh, e2-ogdh, and gcvH), we constructed
mutagenesis plasmids containing an antibiotic resistance marker, aphA (kanR).
The kan resistance gene was PCR amplified from plasmid pBTK with
oligonucleotides TCCC-GGCGCC-CTCGACGATAAACCCAGCGAAC and
TCCC-GGCGCC-CTTTTTAGACATCTAAATCTAGGTAC and sub-cloned into a
unique KasI site engineered between the us and ds regions of
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homologypreviously cloned into pIMAY. Once constructed, the pIMAY gene
replacement constructs were transformed into wild type S. aureus as described
above. Allelic replacement was carried out as already described and gene
replacement mutants were selected on Kan/Neo plates. This procedure was
used to generate the following mutant strains: ΔlipL::kan, Δe2-pdh::kan, Δe2ogdh::kan, and ΔgcvH::kan.
Construction of lipL markerless deletion mutant
The first attempts to construct clean deletions of lipL failed to yield
mutants, likely due to the role of LipL in supporting the function of essential
metabolic pathways in S. aureus. To generate this growth-defective mutant
strain, we constructed the above-mentioned gene replacement mutant carrying
an antibiotic selection marker in place of lipL. This initial strain, ΔlipL::kan, was
then used as parental strain to construct a ΔlipL clean deletion mutant as well as
ΔlipAΔlipMΔlipL. The excision of the antibiotic resistance gene was achieved by
using pIMAY containing lipL us and ds 500bp regions of homology, constructed
as described above leading to the generation of a ΔlipL mutant strain, whose
identity was validated by DNA sequencing.
Construction of ΔlipM ΔlipL
ΔlipL::kan was introduced into ΔlipM via generalized transduction using
bacteriophage ϕ11. The transduction process is described later in this section, in
page 45.
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Construction of ΔlipM ΔlplA2
ΔlipM ΔlplA2 was constructed by transducing ΔlplA2::erm mutation into
ΔlipM using bacteriophage ϕ11. ΔlplA2::erm (NE266) was obtained from the
University of Nebraska USA300 S. aureus bursa aurealis transposon mutant
library.
Construction of ΔlipA Δlip MΔlipL
This mutant was generated from S. aureus LAC with an in-frame deletion
of lipA that was transduced with both a transposon inserted into lipM, obtained
from NE1334 (lipM::erm), and the lipL deletion mutant bearing a kanamycin
resistance cassette (ΔlipL::kan). All transductions were conducted using
bacteriophage ϕ11, generating ΔlipA ΔlipM ΔlipL.
Bacteriophage-mediated generalized transduction
S. aureus specific bacteriophage ϕ11 was used for all transductions. To
package phage with donor DNA, a 3 mL overnight culture of the donor strain
containing the marked gene of interest was incubated with shaking at 37 °C in
TSB-LB media (mixed 1:1) supplemented with 5mM CaCl2 and 5mM MgSO4. The
overnight culture was diluted 1:100 into 10 mL of TSB-LB media supplemented
with 5 mM Cacl2 and 5 mM MgSO4, and was then grown at 37°C in the shaking
incubator for 2.5-3 hours, until reaching a OD 600 nm of 0.3 to 0.9. After this
step, 500 µL of bacterial culture were incubated at room temperature with 10-fold
serial dilutions of ϕ11 phage lysate stock in TMG (10 mM Tris pH 7.5, 5 mM
MgCl2, 0.01% gelatin (v/v)), aiming to achieve an approximate multiplicity of
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infection of 1:1. After 30 minutes, the tubes containing the bacterial suspension
and the phage dilutions were mixed with 3 mL of CY Top agar (Casamino acids 5
g/L, Yeast Extract 5 g/L glucose 5 g/L NaCl 6g/L, 7.5 g/L agar, +/- BCFA as
needed) cooled at 55°C and supplemented with 5 mM CaCl2 and 5 mM MgSO4
and immediately poured on TSA (+/-BCFA as needed) plates supplemented with
the corresponding antibiotic. Once solidified, plates were incubated overnight at
30°C. Following overnight growth, the top agar of 2-3 plates was scraped from
those with confluent plaques using a sterile scoopula and introduced into a single
50 ml tube. Top agar was then suspended in 2 mL of phage buffer (TMG) per
plate worth of Top agar. After extensive vortexing, the tubes were centrifuged for
15 min at maximum speed and the supernatant was filter-sterilized twice using
0.45 µm and 0.22 µm filters. Phage stocks were stored at 4°C.
To transduce recipient strains, overnight cultures containing 20 mL of the
recipient cells in TSB:LB supplemented with 5mM CaCl2 were centrifuged at
maximum speed for 15 min and resuspended in 3 mL TSB:LB media (1:1), also
supplemented with 5 mM CaCl2. Phage infection was carried out by incubating
500 µL serial dilutions (1; 1:10; 1:100) of the bacterial suspension with either 100
µL of ϕ11 phage (108-109 PFU) or 100 µL of TMG buffer (control uninfected) at
room temperature for 30 min, inverting the tubes every 10 min. After incubation,
40 mM final sodium citrate were added to the tubes from a 1M stock solution and
samples were incubated for an additional 30 min period, inverting tubes every 10
min. Samples were then centrifuged at maximum speed for 5 min and washed in
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500 µL LB:TSB medium supplemented with 40mM final sodium citrate. After a
second centrifugation step cells were resuspended in 200 µL TSB containing 40
mM final sodium citrate and 100 µL were spread onto TSA BCFA plates
containing 10 mM sodium citrate supplemented with the necessary antibiotics.
Plates were incubated at 30°C for 24-48 hr or until detection of bacterial colonies.
Potential transductants were later validated via PCR.
Generation of complemented strains
S. aureus complementation strains were generated using plasmid
pJC1111(66) for all strains, except for complementation with lipA, for which we
used the vector pJC1112 (67). These vectors were propagated in E. coli DH5α
and selected for ampicillin resistance. Both pJC1111 and pJC1112 stably
integrate into the SaPI-1 site of the S. aureus chromosome after passage
through strain S. aureus RN9011 containing pRN7203 expressing SaPI-1
integrase, leading to single-copy stable integration of the plasmid.
In order to generate complementation strains using pJC1111 we first
generated constructs that drive expression of the lipM, lipL, pta, pta-lipL, lplA1 or
lplA2 genes under the control of the constitutive PHELP promoter obtained from
pIMAY (68). All oligonucleotides designed for amplification of these complement
constructs are listed in Table 2. Primers designated as C1 and C2 were used to
amplify the PHELP promoter using pIMAY as template DNA. Primers identified as
C3 and C4 were used to amplify the open reading frame corresponding to the
gene of interest for complementation including ~150 nucleotides ds. These two
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DNA fragments were joined via SOEing PCR as described above. All amplicons
were subsequently purified and cloned into pJC1111 after digestion with
restriction enzymes Pst1 and Sac1 and subsequent ligation into pJC1111
generating pJC1111-lipM, pJC1111-lipL, pJC1111-lplA1, pJC1111-lplA2,
pJC1111-pta and pJC1111-pta-lipL.
All complementation plasmids were propagated in E. coli DH5α, followed
by isolation and subsequent electroporation into S. aureus RN9011 and plating
on TSA+BCFA plates supplemented with chloramphenicol and CdCl2. Integrants
were selected based upon CMr CdCl2r and were used as donor strains to
package and transduce the complementation allele into the desired mutant
strain. Complemented strains were selected based on their CdCl2 resistance and
validated via PCR. This process resulted in the generation of strains ΔlipM+lipM;
Δlipl+lipl; ΔlipL+pta; ΔlipL+pta-lipL; ΔlipAΔlplA1+lplA1; ΔlipAΔlplA2+lplA2;
ΔlipMΔlplA1+lplA1; ΔlipAΔlipM+lipM; ΔlipAΔlplA1ΔlplA1+lplA1, and
ΔlipAΔlplA1ΔlplA1+lplA2.
Complementation of ΔlipA was accomplished by amplification of the lipA
gene with its native promoter using primers 0829CompF-Bam and 0829CompREcoRI. The resultant amplicon was cloned into pJC1112 after digestion with
enzymes BamHI and EcoRI. Plasmid propagation in E. coli DH5α was performed
as described above and pJC1112-lipA was subsequently electroporated into S.
aureus RN9011. The chromosomally integrated complementation vector was
later packaged into bacteriophage ϕ11 and transduced into a ΔlipA background.
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Positive transformants were selected based on their erythromycin resistance (3.5
µg/mL) and designated ΔlipA+lipA.
Requirement of lipoate or octanoate for bacterial growth
Bacterial growth curves were carried out in four types of media: RPMI,
RPMI+BCFA, RPMI+Lipoate and RPMI+Octanoate. Overnight cultures were
prepared in triplicate from three individual colonies by inoculating 200 µL of
RPMI+BCFA in adjacent wells of a round-bottom 96-well polystyrene plate
(Corning) followed by incubating overnight with shaking at 200 RPM at 37°C. The
following morning, cells were pelleted at 3,700 rpm for 15 min and washed three
times with 200 µL of RPMI to remove any remaining branched chain carboxylic
acids. After washing cells, 2 µL of each triplicate sample was inoculated into flatbottom polystyrene 96-well plates (Corning) containing 198 µL of RPMI,
RPMI+BCFA, RPMI+25 nM of α-Lipoic acid (Sigma) or RPMI+250 µM Octanoic
acid (Sigma). Bacterial growth was assessed over time by measuring optical
density at 550 nm (OD550), using microplate reader ELx800 (Biotech) until
reaching stationary phase (9-10 hours). Results were graphed and analyzed
using Prism® (GraphPad Software, Inc., San Diego, CA). All growth curves were
conducted at least three times in triplicate. The mean optical density at 550 nm
and standard deviation are shown for all curves.
Whole cell lysate preparation
S. aureus wild type and mutant strains were grown overnight with shaking
at 37°C in 15 mL conical tubes containing 5 mL of RPMI+BCFA media. A
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subculture of 60 µL of these samples was inoculated into 15 mL conical tubes
containing 6 mL of RPMI+BCFA, RPMI+BCFA+5 µM α-Lipoic acid, or
RPMI+BCFA+170 µM Octanoic acid. Samples were incubated with shaking at
200 RPM for 9 hr and bacterial growth was determined by measuring optical
density at 600nm with 1 mL of the culture using a Genesys 10S UV-Vis
spectrophotometer (Thermo). The remaining culture volume was centrifuged at
4,200 rpm for 15 min, the supernatant was discarded, and the bacterial pellets
were stored at -80°C until whole cell lysates were prepared. After thawing frozen
pellets on ice, the bacteria were suspended in 250 µL of PBS and transferred to
screw cap microcentrifuge lysing tubes (Fisher Scientific) containing 250 µL
0.1mm glass cell disruption beads (Scientific Industries, Inc.). Cells were lysed
using a Fast Prep-24 5G (MP Biomedicals) in two sequential steps, at 5.0 speed
for 20 seconds and at 4.5 speed for 20 seconds, each separated by a 5 min
incubation period on ice. After cell disruption, samples were centrifuged at
13,000 rpm for 15 min. 130 µL of the supernatant were collected in
microcentrifuge tubes containing 43 µL of 6X SDS loading buffer (1.11mL 0.9M
Tris-HCl pH 6.8; 0.16g SDS; 2 mL 100% Glycerol; 0.2 mL 14.7M BME; 0.5 mL
0.5 M EDTA, 4 mg bromophenol blue in a 10 mL final volume) and samples were
boiled for 10 min prior to storage at -20 C.
Protein lipoylation assessment
Proteins samples from OD-normalized whole cell lysates were separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) in
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12% polyacrylamide gels at 120 volts for approximately 4 hours. Coomassie
staining was performed to evaluate protein patterns and equivalent loading of
samples using GelCode Blue stain reagent (Thermo) with Precision Plus Protein
Ladder™ (Thermo) used as a molecular weight marker. Briefly, resolved proteins
were transferred from polyacrylamide gels to 0.2 µm PVDF membranes
(Immobilon, Roche) at 200 V for 1 hr in a Quadra Mini-Vertical PAGE/Blotting
System (CBS Scientific). After transfer, membranes were incubated overnight
with PBST (0.1% Tween-20 in PBS) supplemented with 5% BSA at 4°C.
Nonspecific binding of antibody to S. aureus antibody binding proteins, Protein A
and Sbi, was blocked by incubating the membranes with 0.9 mg/mL human IgG
(Sigma) for 1hr. A 1:3000 dilution of rabbit polyclonal anti-lipoic acid antibody
(Calbiochem) in PBST was added to the membrane followed by incubation for 1
hour and three subsequent washed in ~20mL of PBST. Goat anti-Rabbit IgG
(H+L) HRP conjugate (Thermo) was then added at a 1:200 dilution in PBST for
an additional hour followed by three 15 minutes washes in ~20 mL of PBST.
Western blot images were captured on a FluorChem System (Protein Simple)
using SuperSignal West Pico Chemiluminiscent Substrate (Thermo).
Murine systemic infections
All animal experiments were performed in ABSL2 facilities with protocols
approved by Loyola University of Chicago in accordance with the standards of
the Institutional Animal Care and Use Committee. Each experiment was
performed at least three times with cohorts of at least 4 animals. Overnight
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cultures of each strain were inoculated from freshly isolated single colonies
struck out from the freezer the day prior and grown with shaking at 37°C for ~16
hours. A 1:100 subculture into 15 mL of TSB+BCFA was performed followed by
incubation with shaking at 200 rpm, 37°C for 3-4 hr (until reaching optical density
at 600 nm near 1.0). Cultures were then centrifuged for 5 minutes at maximum
speed in a tabletop centrifuge. Cell pellets were washed twice in 5 mL PBS and 2
mL of the final bacterial suspension was added to a 15 mL conical tube
containing 8 mL of PBS. Bacterial suspensions were then normalized with PBS
to reach to an O.D. of 0.32 - 0.33 (1 x 108 CFU/mL). Six to eight week old female
Swiss Webster mice obtained from Envigo (formerly Harlan) were used in all
experiments. Mice were deeply anesthetized with 2,2,2-tribromoethanol (Avertin;
Sigma) via intraperitoneal injection, followed by inoculation with 100 µL PBS
containing 1 x 107 CFU wild type S. aureus or mutant strains directly into the
bloodstream via injection into the retro-orbital venous plexus. After infection, the
remaining bacterial-PBS suspension was plated on TSA-BCFA plates to ensure
viability of cells in PBS and accurate infection inoculum. All strains were fully
viable in PBS and all animals received between (1.0 and 2.0 x 107 CFU). Infected
mice were monitored daily and their kidneys and hearts were isolated
immediately after euthanasia, at 96 hr post infection. Tissues were aseptically
isolated, homogenized and spread onto TSA-BCFA agar plates and incubated
overnight at 37°C in order to enumerate CFU.
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Statistical Analysis
Data analysis was performed via nonparametric 1-way ANOVA using
Prism Graphpad Software V.7 with evaluation of statistical significance done with
Krustal-Wallis multiple comparison post-test. N values in mice experiments are
indicated in the corresponding figures. Growth curves were conducted at least
three times and each one was generated from three independent single colonies.
For each experiment, mean and standard deviations of each data point were
obtained after averaging the values in optical densities. Immunoblots were
conducted a minimum of four times from freshly prepared samples of whole cell
lysates normalized according to their optical density values after 9 hours of
incubation at 37°C.

	
  

	
  

CHAPTER THREE
EXPERIMENTAL RESULTS
Introduction
Staphylococcus aureus is both a skin commensal bacterium and one of
the most relevant human bacterial pathogens, capable of causing minor
infections and life-threatening diseases. In the last few years, there has been an
increase in the onset of S. aureus community-acquired infections, some of which
are caused by hypervirulent strains with an unusual resistance to antimicrobials.
The reason that S. aureus is such a versatile and efficient pathogen stems from
its production of an artillery of virulence factors, along with its ability to hunt for
essential metabolites in nutritionally restricted environments (1, 7).
In a transposon mutagenesis screen designed to identify novel genes with
potential immunomodulatory or virulence functions, Dr. Alonzo identified a
transposon insertion in the gene SAUSA300-0829, encoding a putative lipoate
synthetase (lipA). Supernatant derived from this transposon mutant elicited a
hyper inflammatory response in vivo and in vitro (unpublished data), suggesting a
potential link between lipoate biosynthesis in S. aureus and pathogenesis.
Based on the information available from other bacterial species that harness
lipoate biosynthesis for pathogenesis, and considering the major role for lipoate
43	
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in metabolism in bacterial survival, we hypothesize that the mechanisms of
lipoate acquisition in S. aureus contribute to fitness and pathogenesis by
promoting survival in infectious sites with limited access to lipoate.
Until now, the mechanisms of lipoate biosynthesis and salvage, as well as
the role of lipoate in S. aureus infection biology, remain unknown. The work in
this thesis aimed to address these topics.
The model pathway for lipoate acquisition
The mechanisms of lipoylation in bacteria were first described in
Escherichia coli, considered the model organism on which studies of lipoate de
novo biosynthesis and salvage are based. However, more recent work using
Listeria monocytogenes and Bacillus subtilis revealed significant differences in
the lipoate biosynthesis and salvage pathways of these microorganisms,
suggesting divergence from those of E. coli (16). Due to the moderate amino acid
sequence similarities of S. aureus lipoate biosynthesis and salvage genes
compared to that of E. coli, our work instead derives from comparisons to B.
subtilis lipoate ligases and biosynthesis genes. A simplified pathway for the B.
subtilis lipoate biosynthesis and salvage pathways is depicted in Figure 2.
In B. subtilis, the endogenous synthesis of lipoate occurs in two sequential
steps catalyzed first by an octanoyl transferase (LipM) and then by a lipoate
synthetase (LipA). The first step consists of transferring an octanoate group from
an octanoylated acyl carrier protein (ACP) to a target E2 or H protein subunit.
The second step entails the synthesis of lipoate via the insertion of two sulfur
atoms into the octanoate backbone by LipA. Additionally, B. subtilis requires a
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third enzyme for lipoylation of the target proteins known as LipL, a lipoyl
transferase. By using its lipoate salvage pathway, B. subtilis can bypass both
octanoyl transferase and the lipoate synthetase activities using LplJ, a lipoate
ligase capable of scavenging free lipoate and octanoate from environmental
sources.
Based on the comparison of amino acid identity of S. aureus USA300
isolate FPR3757 lipoate biosynthesis/salvage pathway, this pathogen appears to
be more complex than most other Gram-positive pathogens. Current gene
annotations suggest that S. aureus encodes four putative lipoate ligases and one
lipoate synthetase. According to this annotation, S. aureus would not encode an
octanoyl transferase or a lipoyl transferase. Nevertheless, our bioinformatics
analyses revealed similarities to B. subtilis enzymes involved in de novo lipoate
biosynthesis and salvage and to L. monocytogenes lipoate ligases (.

Table 3 and Fig. 16 Appendix II). For instance, in S. aureus a number of gene

products annotated as lipoate ligases exhibit significant amino acid sequence
identity to B. subtilis: SAUSA-300-0571 54% similarity to LipL and SAUSA3001494 has 62% identity to LipM, indicating that some of these gene products might
be lipoyl/octanoyl transferases. Additionally, in contrast to B. subtilis, which only
has one lipoate ligase (LplJ), S. aureus appears to have two gene products, 0328
and 0930, with predicted ligase functionality. The amino acid sequence alignment
shows that SAUSA-300-0328 has 39% similarity, while SAUSA-300-0930 has
57% amino acid sequence identity to B. subtilis LplJ.
	
  

46
The presence of several putative lipoate ligases and a lipoate synthetase
in the genome of S. aureus implies that this pathogen uses both the de novo
biosynthesis and salvage pathways to acquire lipoate. Interestingly, the existence
of two putative ligases in S. aureus genome is a unique characteristic that
distinguishes this species from other Gram-positive pathogens. The presence of
more than one lipoate ligase is a feature most commonly associated with
organisms that lack a de novo lipoate biosynthesis pathway, such as L.
monocytogenes (16, 19). When we compared 0930 and 0328 with the sequences
coding for L. monocytogenes lipoate ligases, we observed that S. aureus putative
lipoate ligases genes had a moderate (37-41%) amino acid sequence similarity to
L. monocytogenes LplA1 and LplA2 (Table 3 and Fig. 16 Appendix II). This
information may imply that S. aureus encodes two lipoate ligases in addition to
potentially having the enzymes required for lipoate de novo biosynthesis.
Our bioinformatics analyses revealed a number of distinct genes with
potential novel roles in lipoate metabolism within the genome of S. aureus that
deserved further investigation; Figure 3 depicts their genomic localization and
operon organization. For clarity purposes, we have decided to adopt relevant B.
subtilis and L. monocytogenes nomenclatures. Thus, S. aureus genes potentially
involved in lipoate de novo biosynthesis (0829, 1494 and 0571) are named
according to B. subtilis classification (lipA, lipM and lipL, respectively) and the
genes potentially involved in lipoate salvage (0930 and 0328) are named
following L. monocytogenes gene nomenclature (lplA1 and lplA2, respectively).
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Table 3: S. aureus putative genes involved in lipoate metabolism

S. aureus
annotation
Lipoate
synthetase

Lipoate
Ligase

0829 (LipA)

% Identity to B. subtilis / Predicted
function
LipA - Lipoate synthetase (79%)

1494 (LipM)

LipM - Octanoyl transferase (62%)

0571 (LipL)

LipL - Lipoyl transferase (54%)

0930 (LplA1)

LplJ - Lipoate ligase (57%)

0328 (LplA2)

LplJ - Lipoate ligase (39%)

Gene Product

In addition to their similarity to B. subtilis LplJ, the putative lipoate ligases 0930 and 0328 share
between 37%-41% amino acid identity with L. monocytogenes lipoate ligases LplA1 and LplA2.
Due to the fact that S. aureus potentially encodes two lipoate ligases and not one, we have
decided to adopt the nomenclature established for L. monocytogenes for the genes involved in
lipoate salvage. Thus, genes 0930 and 0328 will be referred as LplA1 and LplA2.

The fact that the two ligases in L. monocytogenes have different affinities
for lipoylated peptides in vivo (15) suggests potential unique functions for the S.
aureus lipoate ligases in fitness and pathogenesis.
Of note, two genes associated with lipoate metabolism in S. aureus were
found in operon arrangements. Our bioinformatics analysis of S. aureus gene
arrangements showed that lipL gene is clustered in a putative operon with the pta
gene, presumably responsible to encode the phosphotransacetylase in S.
aureus. Pta is linked to the acetyl CoA kinase (ACKA); together they catalyze the
reversible interconversion of acetyl CoA to acetate and ATP during overflow
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metabolism. The S. aureus 0328 (lplA2) putative lipoate ligase gene is the
second gene with a unique genetic arrangement in the chromosome. It is located
in an extended operon that encodes the sirtuin SirtM and its macrodomain, along
with GcvH-L (53). Interestingly, LplA2 modifies GcvH-L in a lipoylation reaction
that precedes the reversible modification of GcvH-L via SirtM (53).
In a few bacterial and malarial pathogens lplA orthologs can be found near
the genes that encode for E2-PDH and other lipoylated complexes (16). This
association could, in principle, facilitate the association between a lipoate
enzyme to its target proteins. Whether these unique genetic arrangements are
involved in additional functions or regulation of metabolic processes remains to
be tested.
In this study, I planned to determine the biological role of the components
of the lipoate de novo biosynthesis and salvage pathway in S. aureus in order to
fully establish the mechanisms used to acquire this essential cofactor.
Specifically, I aimed to test the hypothesis that not all S. aureus genes annotated
as lipoate ligases are actually involved in lipoate salvage, but rather have
functions related to either lipoate salvage or de novo biosynthesis. Also, I
proposed to study the requirement for this pathway in S. aureus aerobic growth.
Lastly, I aimed to determine whether lipoate de novo biosynthesis and salvage
pathways facilitate S. aureus metabolic adaptability during infection.
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Figure 3: Genome organization of S. aureus lipoate predicted genes
Boxed arrows indicate open reading frames. LplaA2 is encoded in the SirTM operon (53). The
gene encoding the putative lipoyl transferase (amidotransferase) LipL is located in an operon with
the gene coding for the enzyme phosphotransacetylase. The following flanking genes do not
seem to be relevant to lipoate metabolism or regulation: hbp: heme binding protein; mvkmevalonate kinase - rhod: rhodanase domain protein - guf: gene of unknown function.
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For clarity purposes and based in the information provided above, we
propose the following hypothetical pathway for the acquisition of lipoate via de
novo biosynthesis and salvage.

Figure 4: Hypothetical lipoate de novo biosynthesis and salvage pathway
This is a simplified model for lipoate de novo biosynthesis and salvage in S. aureus. Lipoate
biosynthesis is catalyzed by a lipoate synthetase (LS) prior octanoylation of GcvH by an octanoyl
transferase (OT). Lipoyl groups are subsequently transferred to E2 subunits of target proteins by
a lipoyl transferase (LT). In the salvage pathway, lipoate is incorporated from the environment
through the action of lipoate ligases (LPL)
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Construction of deletion mutants to study S. aureus lipoate
pathway
We constructed nonpolar in-frame deletion mutants of all five genes
predicted to be involved in lipoate acquisition, as well as their corresponding
complementation strains to evaluate the requirement for each gene in de novo
lipoate biosynthesis. Based on our bioinformatics analyses, we anticipated the
single deletion mutants of the putative lipoate ligases, ΔlplA1 and ΔlplA2, would
not be sufficient to elucidate the biological role of these enzymes, since these
mutant strains would still be capable of generating lipoate de novo due to the
presence of lipA in each strain. Therefore, in order to ascertain the function of the
lipoate ligases, we also needed to construct double and triple in-frame deletion
mutants of both ligase genes in the background of a lipA deletion mutant. Lastly,
to fully dissect the steps in S. aureus protein lipoylation, we also generated
double deletion mutants of the putative lipoate ligases in both ΔlipM and ΔlipL
genetic backgrounds. As required, we generated complementation strains for all
biosynthesis and salvage mutants displaying phenotypic variances from wild
type.
Table 1 lists the mutant strains generated to fully dissect S. aureus de
novo biosynthesis and salvage pathways. Unless indicated, all strains were
generated by myself or with the assistance of others in the lab. The table also
includes our WT strain USA300 LAC, E. coli DH5α, S. aureus RN4220 and S.
aureus RN9011, all of which were required to propagate plasmids and for the
construction of mutants or their complements. Table 2 lists the oligonucleotides
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used for mutant and complemented strains. For the generation of mutant strains
with growth deficiencies (lipL, e2-pdh, e2-ogdh, and gcvH), we conducted
mutagenesis using plasmids containing a kanamycin resistance marker.
Identification of the lipoylated protein subunits in S. aureus
To elucidate the lipoate de novo biosynthesis and salvage pathway in S.
aureus, we assessed in-frame deletion mutants of the putative genes involved in
lipoate metabolism for their ability to replicate and lipoylate metabolic E2 and H
subunits. As mentioned previously, the literature suggests that S. aureus
possesses four lipoate-containing multienzyme complexes, PDH, OGDH,
BCODH and GCS, each bearing a lipoate molecule attached to a core E2 or H
subunit (16). These lipoylated subunits can be detected as four distinct bands in
immunoblots of S. aureus whole cell lysates using anti-lipoic acid antibody.
GcvH-L, the protein described by Rack et al. (53)
To determine the identity of the four lipoylated proteins detected in S.
aureus whole cell lysates, we evaluated the lipoylation profiles of ΔE2-pdh, ΔE2ogdh and ΔgcvH (H subunit of the glycine cleavage complex) mutants (Figure 5).
constructed by James Grayczyk, a current member of our lab. Unfortunately,
generation of a ΔE2-bcodh mutant was unsuccessful, which suggests a major
role of the branched-chain 2-Oxoacid dehydrogenase complex in maintaining S.
aureus viability. If E2-pdh, E2-ogdh, and gcvH encode proteins that get lipoylated
in S. aureus, then we should see an absence of lipoylation corresponding to the
product encoded by that gene, regardless of whether or not lipoate is
supplemented exogenously.
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Wild type S. aureus lipoylates four protein species at 72, 65, 51, and 23
kilodaltons (Figure 5). After deletion of the E2 subunit of PDH, the ~72 kDa band
is no longer detectable. When we tested ΔE2-ogdh in the presence or absence of
lipoate supplementation, we were unable to detect the ~65 kDa band. The ~23
kDa lipoylated protein observed in the wild type lipoylation profile was no longer
detectable after deletion of the H subunit of the GCS complex, in the presence or
absence of lipoate supplementation. In the absence of exogenous lipoate, the
ΔgcvH mutant has no detectable lipoylated proteins. After supplementation with
lipoate, protein lipoylation was restored to a ΔgcvH mutant, with the exception of
the ~23 kDa protein band. These results indicate that the ~72 kDa lipoylated
protein corresponds to E2-PDH, the ~65 kDa molecular weight species to E2OGDH, and the ~23 kDa protein to the H subunit of the GCS. By process of
elimination, E2-BCODH corresponds to the 51 kDa lipoylated protein band
(Figure 5B). The defects in global protein lipoylation observed for the ΔgcvH
mutant in the absence of lipoate suggests that de novo biosynthesis of lipoate
and subsequent protein transfer in S. aureus occurs sequentially, with GcvH
required for the lipoylation of other protein subunits when lipoate is not
supplemented exogenously.
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Figure 5: Identification of lipoylated proteins in wild type S. aureus
Total cell lysates were obtained from wild type S. aureus or the indicated mutant strains grown
until early stationary phase (9 h). Protein lysates were resolved by SDS-PAGE and detected with
anti-lipoic acid antibody. A. Immunoblot of wild type S. aureus and mutant strains in the absence
(BCFA) or presence of lipoate supplementation (BCFA-LA). B. Identity of each lipoylated protein
in S. aureus.
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The role of S. aureus putative gene products involved in de novo
biosynthesis of lipoate
Assessing the ability to replicate and lipoylate proteins in the presence or
absence of lipoate/octanoate is a useful tool that allows us to identify gene
products with roles in de novo biosynthesis versus lipoate salvage. Any lipoate
biosynthesis mutant whose gene product plays a strict role in de novo
biosynthesis will be rendered auxotrophic for lipoate. To test the roles of lipA,
lipL, lipM, lplA1, and lplA2 in de novo biosynthesis and salvage we generated the
following deletion mutant strains: ΔlipA, ΔlipA + lipA, ΔlipM, ΔlipM + lipM, ΔlipL,
ΔlipL+pta lipL (referred in figure 6 as ΔlipL+ lipL), ΔlplA1, ΔlplA2.
The mutant strains were studied using two straightforward assays, (i)
assessment of bacterial growth and (ii) protein lipoylation in the presence or
absence of lipoate and octanoate. Interestingly, supplementation of 25 nM lipoate
was sufficient to stimulate growth, but 5 µM lipoate was needed to detect lipoate
in the immunoblot. In contrast, higher concentrations of lipoate (250 µM) were
required to promote growth in vitro, while lipoylated proteins after octanoate
supplementation could be detected using 175 µM of octanoate. The high
concentrations of octanoate required for cell replication in our studies were
consistent to what has been found in E. coli, for which it has been shown a
decreased rate of octanoate uptake compared to lipoate uptake (69).
As expected, the lipoate auxotroph ΔlipA mutant was not able to grow in
the absence of lipoate. (Figure 6A), nor was it able to replicate after octanoate
supplementation (Figure 6C), but it could replicate when lipoate was
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supplemented in the medium (Figure 6B), confirming a role in de novo
biosynthesis of lipoate. Immunoblots revealed that ΔlipA is unable to lipoylate the
target proteins when grown in medium that lacks free lipoate (Figure 6A), noted
by the absence of the 4 bands corresponding to lipoylated E2 and H subunits
found in wild type. In contrast, we detect wild-type lipoylation levels after lipoate
supplementation, but not after octanoate supplementation (Figure 6B and C).
These results, along with the successful complementation in ΔlipA + lipA,
supports a role for LipA as a lipoate synthetase, which converts the octanoyl
group to lipoate in GcvH.
A ΔlipM mutant was unable to replicate in RPMI (Figure 6A) without lipoate or
octanoate supplementation. This indicates that the lipM gene product is involved in de
novo biosynthesis despite its annotation as a salvage enzyme. Restoration of ΔlipM
replication was achieved by supplementing either lipoate or octanoate (Figure 6B and C).
Similar to ΔlipA, we detected no lipoylated proteins for ΔlipM in the absence of
exogenous lipoate (Figure 6A). Lipoylation occurred in the presence of lipoate (Figure
6B), presumably because the salvage function performed by the lipoate ligases
remained intact. In addition, lipoylation was also restored after octanoate
supplementation, indicating that LipM is capable of ligating octanoate to the target
proteins, which is then irreversible converted to lipoate by the action of LipA (Figure 6C).
Complementation with lipM further supported the role of the lipM gene product as an
octanoyl transferase. Thus, our results suggest that the lipM gene product is involved in
promoting lipoate biosynthesis from an octanoate precursor in the step that precedes

protein lipoylation, consistent with its role as a putative octanoyl transferase.
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Figure 6: Identification of de novo biosynthesis enzymes
LipA and LipM are required for de novo biosynthesis of lipoate. Growth curves (left) and
immunoblots using anti-lipoic acid antibody (right) of whole cell lysates of strains grown in
RPMI+BCFA (A), RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate (C). All strains were able to
replicate in RPMI+BCFA (Fig. 18 A- Appendix II). Coomassie Blue stained protein patterns are
shown in Figure 20- Appendix II.

	
  

58
We were concerned about the low level of detection of the modified E2BCODH subunit as well as a growth delay observed when assessing a lipM
mutant in RPMI + Octanoate (Figure 6C). We hypothesized that these defects in
lipoylation and replication were caused by a decreased efficiency to incorporate
octanoate through the salvage pathway, as opposed to an inability to transfer an
octanoyl group to BCODH. To test this hypothesis, we repeated immunoblots but
loaded 1.5X the amount of sample, after which we confirmed the presence the
E2-BCODH subunit in the immunoblots (Figure 19). To address the delay in
replication, we titrated the concentration of octanoate in growth curves and
detected normal cell replication after increasing its concentration to 310 µM (data
not shown), suggesting that inefficient use of octanoate caused the lipoylation
defect and reduced growth rate linked to BCODH function in lipM mutants.
The deletion mutant ΔlipL was unable to grow regardless of lipoate and
octanoate supplementation (Figure 6B and C), which suggests that it is not
directly involved in lipoate salvage or lipoate biosynthesis; rather, it appears to be
essential for aerobic growth in some capacity. To rule out the possibility of a
switch in bacterial metabolism we tested aerobic and anaerobic growth for ΔlipA
and ΔlipL on tryptic soy agar (TSA) plates (data not shown). While ΔlipA was
able to replicate in both aerobic and anaerobic conditions, ΔlipL was only able to
grow in anaerobic conditions. This supports the hypothesis that lipL gene product
is an essential component for S. aureus aerobic growth. In addition, ΔlipL
displayed only partial lipoylation regardless of lipoate or octanoate
supplementation (Figure 6A-C). Lipoylated proteins corresponding to E2- OGDH
	
  

59
and GcvH were detected before and after lipoate supplementation. In contrast,
the E2-PDH and E2-BCODH lipoylated proteins were absent. These findings
lead us to conclude that the lipL gene product is likely not involved in de novo
biosynthesis or in lipoate salvage per se, yet its presence is required for survival
in vitro and efficient lipoylation of at least two of the five E2 subunits. The fact
that the E2-PDH and E2-BCODH bands are missing in the lipoylated protein
profile for all conditions tested indicates that lipL encodes a protein responsible
for transferring lipoate groups to those two proteins. We can presume that the
lack of lipoylation in E2-PDH and E2-BCODH is probably causing the replication
arrest observed in our growth curves. Lastly, we can infer from Figure 6 that
protein lipoylation might be occurring in sequential steps, which would coincide
with what has been described in the literature for B. subtilis (16, 54, 61).
Construction of the complementation strain for ΔlipL was more
complicated than expected. We were unable to restore growth or protein
lipoylation after introduction of pJC1111-lipL. After examining the genetic
organization of lipL, we noticed that this gene is located in what appears to be a
two-gene operon along with pta (SAUSA300-0570), the gene coding for the
phosphate acetyl transferase (Pta) (Figure 3). Pta is the enzyme responsible for
the synthesis of acetyl phosphate from acetyl-CoA and phosphate and, along
with the enzyme acetyl kinase (AckA), is required for S. aureus survival during
overflow metabolism (70). Because of this genetic arrangement, we decided to
test the hypothesis that the entire pta-lipL operon is required for full
complementation of a ΔlipL mutant. Indeed, we were able to successfully
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complement a ΔlipL mutant after transduction of the integrative plasmid
pJC1111-pta-lipL (Figure 7). Further investigation of the interplay between Pta
and LipL will help us elucidate potential connections between metabolic output
and protein lipoylation or novel regulatory schemes associated with protein
lipoylation that may dictate shifts in metabolic flux.
Lastly, the putative lipoate ligase deletion mutants, ΔlplA1 and ΔlplA2,
were able to replicate and to lipoylate proteins in all three conditions tested
(Figure 6A-C), which suggests that these enzymes are not involved in de novo
biosynthesis, and may play a role in lipoate/octanoate salvage. However, we
cannot yet assign a lipoate ligase function to these two genes until we test them
in a genetic background that cannot use de novo biosynthesis to generate
lipoate.

E2-PDH
E2-OGDH
E2-BCODH

GcvH

Figure 7: Complementation of ΔlipL
ΔlipL growth and lipoylation defects are restored after complementation with the pta-lipL operon.
Growth curves (left) in RPMI and immunoblots with anti-lipoic acid antibody (right) from whole cell
lysates of strains grown in RPMI+BCFA.
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The requirement of lipoate de novo biosynthesis in vivo
Our results have revealed that S. aureus requires the lipoate salvage
pathway to replicate in vitro when de novo biosynthesis is not functional. To test
whether or not de novo biosynthesis of lipoate is required for survival of S.
aureus in vivo, we assessed the ability of a ΔlipA mutant to colonize and infect
mice using murine sepsis model. Six to eight week old female Swiss Webster
mice were infected by retro-orbital venous plexus injection with ~1x107 colony
forming units (CFU)/mL of WT, ΔlipA and ΔlipA + lipA and infection was allowed
to proceed for 96 hours. We suspected that if de novo biosynthesis of lipoate
were promoting S. aureus survival in vivo, then we should detect a decreased
bacterial burden in infected organs. In contrast, if de novo of lipoate were
dispensable, we should observe equivalent pathogenesis to that of wild type.
In the kidney, we detected no significant changes in bacterial burden
between the wild type strain, ΔlipA or ΔlipA-lipA (Figure 8). However, in the heart,
we observed a drastic decline in the ability of ΔlipA to colonize, with a 3-log
reduction in bacterial CFU and a significant number of mice (N=8) having no
recoverable bacteria. We also evaluated S. aureus seeding in liver and spleen of
mice after systemic infection. Regrettably, no CFU for WT and other strains were
detected in these tissues at 96 hours post infection.
From these results, we can conclude that de novo biosynthesis of lipoate
is required to colonize the heart of mice in a systemic model of infection. Based
on our previous results, we hypothesize that the efficient infection in the kidneys
	
  

62
relies upon the enzymatic activity of the lipoate ligases to maintain infectivity.
Thus, when the ability to synthesize lipoate is blocked, S. aureus can satisfy the
requirement for lipoate by scavenging this cofactor from the kidney environment.
To fully assess the validity of this assumption, we will need to identify the lipoate
ligases and determine their ability to incorporate lipoate in vivo.

Figure 8: Requirement for lipoate de novo biosynthesis in vivo
De novo biosynthesis of lipoate is required for infection of the heart but not the kidney during
sepsis. Bacterial burden displayed as log10CFU in kidneys and heart at 96 hours post
7

bloodstream infection with 1.0 x 10 CFU of WT (N=8), ΔlipA (N=19) and ΔlipA + lipA (N=8).
Median expressed as a measure of central tendency. In the heart, only one mouse had no
recoverable bacteria, compared to 8 mice with undetectable CFU in the lipA deletion mutant.
Statistics were calculated via nonparametric 1-way ANOVA and statistical significance in CFU
values was evaluated using Krustal-Wallis multiple group comparisons. Evaluation of the results
found in the heart between WT and ΔlipA showed a P<0.05 (*). Statistical significant differences
where found in ΔlipA compared to ΔlipA + lipA had P<0.001 (**).
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Characterization of the lipoate ligases constructed in a ΔlipA
background
To evaluate the lipoate salvage function in isolation, we generated ligase
mutants in a ΔlipA mutant background of S. aureus. This blocks the synthesis of
lipoate de novo and permit assessment of ligase activity. The following mutants
were constructed: ΔlipA ΔlplA1, ΔlipA ΔlplA2 and their complemented strains
ΔlipA ΔlplA1+lplA1, ΔlipA ΔlplA2+lplA2. Additionally, we generated ΔlplA1
ΔlplA2, which lacks both putative lipoate ligase genes, but is still capable of
engaging in de novo biosynthesis of lipoate. With these mutants, if the genes
encoding putative lipoate ligases are involved in lipoate salvage, then they
should no longer replicate and lipoylate when supplemented with lipoate.
As expected, the double ligase mutant ΔlplA1 ΔlplA2 replicates and
lipoylates proteins in all three conditions tested (Figure 9). In contrast, ΔlipA
ΔlplA1 and ΔlipA ΔlplA2 were unable to replicate and lipoylate proteins in RPMI
lacking lipoate or octanoate (Figure 9A and C). When supplemented with lipoate
(Figure 9B), a ΔlipA ΔlplA2 replicates normally and exhibits WT lipoylation
profiles. Thus, lipoate salvage in vitro appears to depend on LplA1. Strikingly,
when we tested the ΔlipA ΔlplA1 strain, we saw no restoration of growth and the
ability to lipoylate proteins was lost, implying LplA1 is the primary lipoate ligase in
vitro. Importantly, complementation of ΔlipA ΔlplA1 with their corresponding
genes fully restored wild type growth phenotypes and lipoylation profiles after
lipoate supplementation (Figure 9B).
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Figure 9: Assessment of lipoate ligases in the background of ΔlipA
LplA1 behaves as a lipoate ligase in vitro. Growth curves (left) and immunoblots detected with
anti-lipoic acid antibody (right) of whole cell lysates of strains grown in RPMI+BCFA (A),
RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate (C). All strains were able to replicate in
RPMI+BCFA (Fig. 18 B- Appendix II). Coomassie Blue stained protein patterns are shown in
Figure 20- Appendix II.
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These results suggest that the two putative lipoate ligases, LplA1 and
LplA2 do not behave similarly in vitro, with only LplA1 playing a role in lipoate
salvage under these conditions. Nevertheless, it is possible that we are not
detecting LplA2 activity with the methods used in this study. Alternatively, lplA2
might not be expressed in broth culture. Studies evaluating LplA2 preferred
lipoylated substrates and target proteins as well as lplA2 expression would be
necessary to fully understand the behavior of LplA2 in vitro.
Evaluation of the lipoate salvage pathway in a triple deletion
mutant strain
Our results with ligase mutants constructed in a lipA deletion background
showed that LplA2 was not engaging in lipoate ligation in vitro. This contrasted
with the observations in L. monocytogenes, in which both of the lipoate ligases
are capable of using lipoate in vitro, albeit with different affinities (61).
Additionally, the literature indicates that LplA2 is encoded in an operon
that is upregulated under oxidative stress conditions (52, 53), so it is plausible
that this gene is not sufficiently expressed under our experimental conditions. To
test whether the constitutive expression of LplA2 renders protein lipoylation and
allows replication in vitro, we generated the ΔlipA ΔlplA1 ΔlplA2 mutant strain
and we individually complemented this strain with lplA1 and lplA2. If LplA2 has
the ability to ligate lipoate in vitro, then we should observe restoration of wild type
growth and protein lipoylation phenotypes when supplemented with lipoate.
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Figure 10: Assessment of lipoate ligases in triple deletion mutants
LplA2 facilitates lipoylation of E2 subunits and GcvH in vitro when constitutively expressed.
Growth curves (left) and immunoblots detected with anti-lipoic acid antibody (right) of whole cell
lysates of strains grown in RPMI+BCFA (A), RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate
(C). All strains were able to replicate in RPMI+BCFA (Fig. 18 D- Appendix II). Coomassie Blue
stained protein patterns are shown in Figure 21 where necesar- Appendix II.

	
  

67
As expected, ΔlipA ΔlplA1 ΔlplA2 was incapable of replication and protein
lipoylation in the absence and presence of supplements (Figure 10). In contrast,
ΔlplA1 ΔlplA2 replicates and lipoylates proteins at wild type S. aureus levels in all
three conditions tested. The supplementation of lipoate in a triple mutant
complemented with lplA1 also restored protein lipoylation and growth to wild type
levels. Interestingly, complementation with lplA2 led to partial protein lipoylation
and no restoration of growth. These results suggest that LplA2 is capable of
ligating lipoate in vitro when constitutively expressed albeit at levels that are
insufficient to restore growth.
The contribution of lipoate ligases to lipoate salvage in a lipM
deletion background
We constructed strains in a ΔlipM mutant background to determine
whether the lipoate ligases LplA1 and LplA2 play a role in salvage of lipoate or
octanoate during the initial steps of lipoate de novo biosynthesis. A ΔlipM single
deletion mutant behaved as previously described (Figure 6), while a ΔlipA ΔlipM
double mutant was incapable of lipoylating proteins or replicating in all conditions
tested due to the blockade of the lipoate de novo biosynthesis pathway (Figure
11). As anticipated, ΔlipM ΔlplA1 and ΔlipM ΔlplA2 mimicked the results
observed for the lipoate ligases in the background of a ΔlipA when media was
supplemented with lipoate (Figure 9B and Figure 10B). LplA2 function, as
assessed via ΔlipM ΔlplA1, showed no role for salvage of octanoate. In contrast,
the growth phenotype and lipoylation profile of ΔlipM ΔlplA2 revealed that LplA1
is involved in incorporating octanoate in vitro (Figure 11C).
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Figure 11: Assessment of lipoate ligases in the background of ΔlipM
LplA2 is capable of ligating octanoate through the salvage pathway. Growth curves (left) and
immunoblots detected with anti-lipoic acid antibody (right) of whole cell lysates of strains grown in
RPMI+BCFA (A), RPMI+BCFA+Lipoate (B), RPMI+BCFA+Octanoate (C). All strains were able to
replicate in RPMI+BCFA (Fig. 18 C- Appendix II). Coomassie Blue stained protein patterns are
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This information was confirmed by the ΔlipM ΔlplA1+lplA1 strain, for which
we observed restoration of a ΔlipM mutant protein lipoylation and growth
phenotype. Taken together, these data suggest that LplA1 can provide
octanoylated proteins to LipA, independently of the enzymatic activity of LipM.
Assessment of the requirement for lipoate salvage in vivo
We have demonstrated that biosynthesis of lipoate is required for heart
infection in mice during sepsis. In contrast, the enzymatic function of LipA was
dispensable for kidney infection. Therefore, we tested the hypothesis that the
salvage of lipoate supports efficient infection in the renal tissue. Additionally, we
tested whether or not LplA2 play a role in lipoate salvage during infection.
We infected mice with either the single deletion mutants of the lipoate ligases;
with the ΔlplA1 ΔlplA2 double mutant or with the complemented strains ΔlplA1
ΔlplA2 + lplA1 and ΔlplA1 ΔlplA2 + lplA2. Our results show that in the kidneys,
ΔlplA1 and ΔlplA2 had bacterial burden levels equivalent to those detected in
both the wild type strain and the lipA deletion mutant, indicating that neither
LplA1 nor LplA2 are essential to colonize this tissue (Figure 12). Remarkably,
kidney infection with a ΔlplA1 ΔlplA2 double mutant was severely compromised
in the host, showing a 4-log reduction in bacterial burden compared to the wild
type strain. This suggests that both lipoate ligases are required for efficient
infection of the renal tissue. Interestingly, bacterial seeding after infection with
ΔlplA1 ΔlplA2 was not completely eliminated, supporting the notion that lipoate
de novo biosynthesis contributes to some degree during infection of the kidneys.
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Figure 12: Assessment of the requirement for lipoate salvage in vitro
Lipoate ligases LplA1 and LplA2 are individually required for efficient infection of the kidney.
Bacterial burden displayed as log10CFU in kidneys and heart at 96 hours post bloodstream
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ΔlipA1 and ΔlipA1ΔlipA2 + lplA2 (*). In the heart, a P<0.05 value of statistical difference was
observed for WT compared to ΔlipA.

Additionally, bacterial burden levels for ΔlplA1 ΔlplA2 + lplA1 or ΔlplA1 ΔlplA2 +
lplA2 were near those found for the wild type strain. Taken together, these data
suggest that both lipoate ligases can compensate for one another to facilitate
infection of the kidneys (Figure 12).
The results for heart infection revealed that bacterial infection in this tissue
is dependent on the de novo biosynthesis of lipoate. When we infected mice with
ΔlplA1, ΔlplA2, or with ΔlplA1 ΔlplA2, no significant alterations in bacterial burden
were detected. This indicates that lipoylation through the salvage pathway does
not contribute significantly to pathogenesis of the heart (Figure 12).
In sum, we can conclude that de novo lipoate biosynthesis is essential for
S. aureus survival in the heart during sepsis. Additionally, S. aureus
pathogenesis in the kidneys relies upon the lipoate salvage pathway, a process
that is supported by both lipoate ligases LplA1 and LplA2.
Evaluation of the role of the lipoyl transferase LipL in de novo
biosynthesis and salvage of lipoate
Our previous experiments showed that LipL transfers lipoyl groups to E2PDH and E2-BCODH; nevertheless, our assessments were insufficient to define
which enzyme is responsible for the lipoylation of E2-OGDH and GcvH. To gain
knowledge on this matter, we generated a set of mutant strains constructed in a
ΔlipL background and performed immunoblots of ΔlipA ΔlipL; ΔlipM ΔlipL; ΔlipL
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ΔlplA1; ΔlipL ΔlplA2; and ΔlipL ΔlipA ΔlipM. We did not execute growth curves in
RPMI supplemented with lipoate or octanoate for this mutant strains due to the
known replication phenotype found for lipL deletion mutant (Figure 6).
Nevertheless, cells were capable of replicating in BCFA-RPMI, as shown in
Figure 18A, Appendix II for ΔlipL (results for the rest of the mutants described in
this section are not shown).
In the absence of supplements, ΔlipA ΔlipL, ΔlipM ΔlipL and ΔlipL ΔlipA
ΔlipM failed to lipoylate proteins (Figure 13). In the same conditions a
ΔlipLΔlplA2 double mutant mimicked a ΔlipL single deletion mutant, indicating
that LplA2 is not involved in lipoylating E2-OGDH or GcvH. Interestingly, this was
not the case for ΔlipLΔlplA1, for which we detected lack of lipoylation for E2 OGDH. This result implies that LplA1 is capable of transferring a lipoyl group
from GcvH to the E2-OGDH without lipoate or octanoate supplementation
independently of LipL.
The supplementation of lipoate restores the ΔlipL protein lipoylation
phenotype in all tested mutants with the exception of ΔlipLΔlplA1, for which the
E2-OGDH lipoylated band remains absent (Figure 13B). Lipoate supplementation
for ΔlipL ΔlipA ΔlipM also indicates that LplA1 is efficient at ligating lipoate to E2OGDH and GcvH, and it also reveals that this process can occur trough a
mechanism that is independent of the enzymatic activity of LipA, LipM and LipL.
Furthermore, GcvH gets lipoylated in both ΔlipLΔlplA1 and ΔlipM ΔlipL
mutant strains after octanoate supplementation, yet E2-OGDH remains
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undetectable (Figure 13C). In contrast, lipoylation of GcvH does not occur in
ΔlipA ΔlipM ΔlipL. These results indicate that both LplA1 and LipM can attach
octanoate to GcvH, but also, that LplA1 is incapable of ligating octanoate onto
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Taken together, these data support the hypothesis that protein lipoylation
initiates through octanoylation of GcvH, either via the enzymatic activity of LipM
or the function of LplA1. Additionally, it implies that lipoate de novo biosynthesis
occurs in sequential steps in S. aureus. This process initiates through lipoylation
of GcvH and continues with the transfer of the lipoyl group to E2-PDH and E2BCODH via the action of LipL. In contrast, lipoylation of E2-OGDH via LplA1
seems to occur exclusively through ligation of free lipoate.
Evaluation of S. aureus requirement for lipoate during infection
and the individual contribution of lipoate ligases in vivo
Efficient infection of the renal tissue during sepsis depends on lipoate
scavenging. When we tested ΔlplA1 ΔlplA2 in this infection model we observed a
significant decrease in bacterial burden compared to the wild type. Nevertheless,
we could still detect bacterial colonization, meaning that the de novo biosynthesis
pathway, which is functional in this mutant, was possibly enabling infection in this
tissue. To determine whether or not S. aureus requires lipoate acquisition in any
capacity to survive during sepsis we used a ΔlipA ΔlplA1 ΔlplA2 triple mutant that
lacks the ability to engage in both de novo biosynthesis and salvage of lipoate.
This mutant was completely avirulent in vivo (Figure 14), indicating that S. aureus
requires lipoic acid in vivo and cannot switch to other metabolic pathways
(anaerobic metabolism) to bypass this requirement. Infection with the
complementation strains ΔlipA ΔlplA1 ΔlplA2 + lplA1 and ΔlipA ΔlplA1 ΔlplA2 +
lplA2 confirmed our previous results; both lipoate ligases can incorporate lipoate
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in vivo, promoting bacterial replication in the host. In sum, these results allowed
us to validate and further characterized the de novo biosynthesis and salvage
pathway but, more importantly, provided insight into one of the mechanisms used
by S. aureus to better colonize its host.
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Figure 14: Assessment of the requirement for lipoate acquisition
S. aureus requires acquisition of lipoate to infect the kidney. Either LplA1 or LplA2 suffice to
restore infection in the renal tissue. Bacterial burden displayed as log10CFU in kidneys and heart
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at 96 hours post bloodstream infection with 1.0 x 10 CFU of WT (N=21), ΔlipAΔlipA1ΔlipA2
(N=20), ΔlipAΔlipA1ΔlipA2 + lplA1 (N=14) and ΔlipAΔlipA1ΔlipA2 + lplA2 (N=15). Median is
expressed as a measure of central tendency. Statistics were calculated via nonparametric 1-way
ANOVA and statistical significance was evaluated using Krustal-Wallis multiple group
comparisons. Analysis of the statistical significant differences in CFU showed P<0.0001 (****),
P<0.001 (***) and P<0.05 (*) value of statistical difference was observed for WT compared to
ΔlipA. .

	
  

CHAPTER FOUR
DISCUSSION
The central hypothesis of this work was that lipoate acquisition
mechanisms are capable of promoting S. aureus infectivity. In order to
test this hypothesis, we first needed to elucidate the mechanisms by
which S. aureus lipoate acquisition occurs. We used bacterial genetics
techniques to generate mutant strains containing deletions in the five
lipoate biosynthesis and salvage genes of S. aureus. The mutants were
later assessed for their ability to lipoylate proteins and to replicate in vivo
and in vitro in the presence or absence of lipoic acid or octanoic acid. A
working model for the lipoate de novo biosynthesis and salvage pathway
in S. aureus is shown in Figure 15.
During the course of this work, we confirmed that S. aureus has four
lipoylated enzyme complexes (PDH; OGDH; BCODH and GCS) that
require a lipoate modification on one of its subunits in order to become
active. GcvH-L is an additional protein that bears lipoate but was
undetected under the conditions tested in our work. This protein is
contained in an operon that is presumed to be upregulated under oxidative
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stress conditions, which could explain why we were unable to detect it in
our immunoblots (53). Our work also determined that S. aureus uses two
mechanisms to incorporate lipoate onto these enzyme complexes, the de
novo biosynthesis and the salvage pathway. Additionally, we have
characterized the gene products involved in this pathway and found
unexpected results that might suggest a potential role of lipoate
biosynthesis enzymes in regulation of metabolic processes in S. aureus
and in resistance to host defenses.
After elucidation of the lipoate de novo biosynthesis and salvage
pathway in S. aureus, we evaluated the roles of lipoate metabolism in vivo
using a mouse model of sepsis. We measured the ability of mutant strains
to colonize host tissues and we found that, during sepsis, S. aureus relies
either on lipoate de novo biosynthesis or salvage to infect the host. This
process occurs in a tissue-dependent manner and confirms our hypothesis
that mechanisms of lipoate acquisition contribute to S. aureus fitness and
pathogenesis. Importantly, we were able to confirm that lipoate
metabolism and, by extension, aerobic metabolism, is essential for S.
aureus pathogenicity.
Lipoate de novo biosynthesis and salvage pathway
LipA and LipM are lipoate de novo biosynthesis enzymes
As shown in Figure 6, we were able to confirm the hypothesis that LipA is
the lipoate synthetase in S. aureus, since a ΔlipA mutant could only replicate and
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lipoylate proteins after lipoate supplementation. LipM was identified as the
octanoate transferase after observing restoration of growth and protein lipoylation
to wild type levels when lipoate or octanoate were supplemented in the culture
medium. The contribution of LipA and LipM to de novo biosynthesis of lipoate
was further confirmed after the assessment of the double deletion mutant ΔlipA
ΔlipM and the complemented strain ΔlipA ΔlipM + lipM, both of which could not
be rescued by octanoate supplementation Figure 11.
Only LplA1 is required for in vitro utilization of lipoate
In silico analysis predicted that S. aureus encodes two lipoate
ligases involved in salvage of lipoate, LplA1 and LplA2. The combined
information, provided by the deletion mutants of the lipoate ligase genes
and the mutants constructed in the background of ΔlipA revealed that only
LplA1 is involved lipoate scavenging in vitro. This was evident in the ΔlipA
ΔlplA1 mutant, for which LplA2 was incapable of facilitating growth and
protein lipoylation regardless of lipoate supplementation Figure 9.
Previous research has shown that S. aureus LplA2 lipoylates GcvHL, a glycine cleavage system H-like protein that is encoded in the same
operon as LplA2 (53). We were not able to detect lipoylation of GcvH-L
during the course of this thesis, probably due to reduced expression of
this operon in vitro (52). Yet, a few additional hypotheses that are not
mutually exclusive could explain the observed lack of observable activity
for LplA2 in vitro.
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First, LplA2 might be less efficient at ligating free lipoate compared
to LplA1. This was the case for differences observed between L.
monocytogenes lipoate ligases (19, 61). Another hypothesis is that S.
aureus LplA2 uses a different substrate in place of free lipoate, such as
peptide-bound lipoate. This is supported by the investigations conducted
by Rack et al., in which S. aureus LplA2 was shown to lipoylate the noncanonical GcvH using lipoamide, a lipoic acid derivative (53). Finally,
lplA2 may not being expressed under the conditions tested in this thesis.
Support for the last hypothesis comes from results observed after
complementing back the lplA2 gene in the triple mutant ΔlipM ΔlplA1
ΔlplA2 ( Figure 12 ). The ΔlipM ΔlplA 1ΔlplA2 + lplA2 strain displayed partial
lipoylation of proteins, a result most likely explained by the nature of the
complementation construct, which expresses lplA2 constitutively.
Additional support for the regulation hypothesis is derived from the
fact that lplA2 is known to be encoded in an operon that seems to be
upregulated under oxidative stress conditions (52, 53). We could directly
test this by generating a transcriptional reporter fusion to gfp followed by
evaluating GFP expression under redox stress conditions. Such stress
conditions are easily induced in vitro using oxidative stressors capable of
promoting formation of disulfide bonds, such as H 2 O, the redox cycling
drug menadione, or diamide, a compound specific for thiol oxidation (5).
Oxidative conditions can be assessed in vivo by co-culturing S. aureus
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with purified macrophages and neutrophils. If the lplA2 operon is induced
by oxidative stress, we expect GFP fluorescence to increase in the
presence of the reactive oxygen intermediates (71).

Figure 15: Model pathway for lipoate acquisition in S. aureus
S. aureus synthetizes lipoate through the de novo biosynthesis pathway and
incorporates free lipoate from the environment via the salvage pathway. We propose
this model pathway for S. aureus based in the combination of our results and data from
other authors (16, 53, 59, 61). In the salvage pathway, LplA1 is capable of lipoylating
GcvH both in vivo and in vitro. In contrast, we could only determine salvage of lipoate in
vivo for LplA2, supporting the hypothesis that lplA2 containing operon is upregulated
during oxidative stress conditions, as stated by Rack et al (52). These authors showed
that LplA2 is also involved in salvage of lipoate in vivo by being capable of lipoylating
both GcvH and GcvH-L, although the latter with grater affinity. Both LplA1 and LplA2
were shown to be required for optimal renal infection in the kidneys. We have also
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shown that LplA1 was capable of attaching octanoate to GcvH and lipoate to E2OGDH, although we consider this to be secondary to its main role as a salvage enzyme
involved in lipoylation of GcvH. The biological importance of these observations is
currently under investigation in our laboratory

LplA1 can ligate free octanoate
Assessing the putative lipoate ligases in the background of a ΔlipM
mutant increased our knowledge of the contribution of these enzymes to
the salvage of octanoate. As shown in the immunoblots and growth curves
of ΔlipM ΔlplA2, ΔlipM ΔlplA1 and ΔlipM ΔlplA1 + lplA1 LplA1 was capable
of ligating the lipoate precursor, octanoate, bypassing ΔlipM (Figure 11).
Lipoate then proceeds via the lipoate synthetase LipA, which would
convert the octanoyl group to lipoate. Whether LplA1 is capable of using
both free and peptide-bound octanoate is unknown. In contrast to what
was observed after the complementation of LplA2 in a ΔlipA ΔlplA2 +
lplaA2 mutant strain, the constitutive expression of lpla2 in ΔlipM ΔlplA2
did not restore growth or protein lipoylation, suggesting that LplA2 cannot
catalyze octanoate ligation under our experimental conditions.
Interestingly, lipoate ligase-mediated octanoylation was previously
observed for LplA1 of L. monocytogenes as well as LplJ of B. subtilis (54,
61). This argues in favor of a lipoate ligase-dependent pathway for protein
octanoylation that is independent of LipM. From our knowledge of the
lipoate biosynthesis and salvage pathway in other species and our own
results, we postulate that the octanoyl group is being attached to GcvH via
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LplA1 and, subsequently, LipA inserts two sulfur atoms, converting the
octanoyl moiety to a lipoyl moiety.
A deep assessment of the octanoylation capacity of LplA1, as well
as LipM is complicated due to the endogenous biosynthesis of octanoate.
Nevertheless, octanoylation of GcvH could be tested through enzymatic
studies in vitro or by generating a triple mutant of the lipoate ligases and
the lipoate synthetase in the background of a fatty acids auxotroph strain.
LipL is required for efficient protein lipoylation in S. aureus
Based on bioinformatics analyses and similarities to B. subtilis LipL,
the product of the 0571 gene, LipL, is predicted to encode a lipoate
transferase. Growth assessment of a ΔlipL mutant showed that this strain
was incapable of replicating even after supplementation with lipoate or
octanoate. Additionally, we observed lipoylation defects in a ΔlipL mutant,
such that only lipoylated GcvH and E2-OGDH could be detected.
Replication of ΔlipL in RPMI BCFA medium was normal (Figure 18A
Appendix II), indicating that this strain was metabolically competent and
only the absence of functional E2-PDH and E2-BCODH was responsible
for growth arrest. We suspect ΔlipL replication arrest could be explained
by the lack of a functional BCODH, which causes alterations in membrane
fluidity due to defects in short branched-chain fatty acid biosynthesis and
incorporation into the lipid bilayer (11, 54, 59), although this remains to be
tested.
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Importantly, the results observed in Figure 13 were consistent with
the findings published on B. subtilis LipL, which showed abrogated growth
in vitro and partial protein lipoylation in a lipL deletion mutant (59), as well
as with the role of LipL as a lipoyl-transferase in L. monocytogenes.
Although we do not have direct evidence of LipL transferring lipoylated
groups to E2-OGDH, based on the role of LipL in other species we
presume this protein is capable of attaching a lipoyl molecule to this
subunit. We demonstrated that LplA1 is capable of lipoylating E2-OGDH
when LipL is absent, but we suspect this is not the predominant lipoylation
mechanism for this subunit under normal conditions. Most likely,
lipoylation of E2-OGDH is secured via LipL. Therefore, we postulate that
LipL is a lipoyl transferase in S. aureus and is the sole enzyme involved in
modifying the E2 subunits of lipoylated enzyme complexes in S. aureus.
GcvH is the first protein to be lipoylated during de novo
biosynthesis
The literature argues that GcvH is the first protein to get lipoylated
in the lipoate biosynthesis and salvage pathway (11, 61, 70). From an
evolutionary perspective, GcvH is believed to be an ancestral protein
bearing the first lipoyl domain that arose in nature (11). This notion is
based on the conserved structure and role of the glycine cleavage
complex, which catalyzes a process that is virtually essential throughout
nature. This contrasts with the TCA cycle or branched chain fatty acid
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biosynthesis, which are known to be dispensable in many organisms (11,
72). The hypothesis that GcvH is the first intermediate in lipoate
acquisition mechanisms is supported by the fact that Achaea and Bacteria
species that lack the glycine cleavage complex (GCS) can bypass the
requirement for lipoylated enzyme complexes such as PDH, OGDH or
BCODH, and do not encode genes involved in lipoate metabolism (11,
72). Additionally, in eukaryotic microorganisms, such as P. falciparum and
T. gondii, GcvH is almost always exclusively localized in the mitochondria
and its lipoylation occurs through lipoate scavenging. This connection
between the compartmentalization of GcvH in this endosymbiotic
organelle and its lipoylation via salvage of lipoate is very interesting and
supports the notion of GCS as the first lipoylated system in nature (16, 60,
62).
Several lines of evidence in our work also support the notion that de
novo biosynthesis and salvage of lipoate is initiated with GcvH. The first
evidence comes from the immunoblots of the ΔgcvH strain grown in the
absence or presence of lipoate. When GSC is not functional, lipoylation
appears to be blocked for E2-PDH, E2-OGDH and E2-BCODH subunits
but when lipoate salvage is permitted al E2 subunits get lipoylated,
indicating that GcvH lipoylation is a requirement for de novo biosynthesis
of lipoate. Furthermore, the ΔlipL ΔlipA strain, which lacks the lipoate
synthetase, is unable to lipoylate GcvH when grown without supplements
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despite having LipM and LplA1 present. The same results are seen for a
ΔlipL ΔlipM double mutant in the absence of supplements. In this case,
LplA1 is present, but there is no exogenous lipoate available. We only see
lipoylation of GcvH in a ΔlipL ΔlplA1 mutant, which indicates that LipM is
transferring octanoate from the ACP to GcvH.
When we supplement lipoate, we see lipoylation of GcvH in ΔlipL
ΔlipA, ΔlipL ΔlipM and ΔlipL ΔlplA1 strains. The fact that OGDH cannot be
lipoylated in a ΔlipL ΔlplA1 mutant under this condition supports the idea
that LipM can only attach octanoate to GcvH, and that transfer of the
lipoate group to the remaining 2-Oxoacid dehydrogenases cannot proceed
when LipL is absent. The only exception to this case is direct lipoylation of
E2 OGDH using free lipoate, which can be mediated by what appear to be
accessory functions of LplA1. Supplementation of octanoate further
supports the notion that de novo biosynthesis of lipoate initiates
exclusively through GcvH. If we compare ΔlipL ΔlipM in RPMI alone and
after octanoate supplementation we observe that LplA1 must ligate
exogenous octanoate to GcvH because lipoyl-GcvH is detected by
immunoblot. Additionally, a ΔlipL ΔlplA1 mutant grown under lipoate
restriction reveals that LipM exclusively transfers endogenous octanoate
from an acyl carrier protein to GcvH. Our findings are consistent with prior
work demonstrating the B. subtilis octanoyl transferase LipM and E. coli
LipB catalyze the transfer of an octanoyl moiety from octanoyl-ACP to the
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H subunit of the glycine cleavage system (54, 55, 57). Additionally, B.
subtilis lipoate ligase LplJ has been shown to use free octanoate for GcvH
octanoylation (11). Furthermore, GcvH has also been shown to be the first
protein subunit lipoylated in L. monocytogenes via LplA1 (61).
Thus, based on support from the literature and from our own
findings, we propose that S. aureus LipM is using ACP-bound octanoyl
groups to modify GcvH and that LplA1 is capable of using octanoate for
the same purpose. Importantly, we cannot yet determine with absolute
certainty that LipM only uses ACP-derived octanoate or whether it is
capable of attaching free octanoate to GcvH. Purifying this enzyme and
testing if it is capable of transferring the octanoyl group from an ACP to
other protein subunits in the absence of exogenous sources of octanoate
could serve to determine the precise octanoylation capacity of LipM.
Moreover, constructing a strain deficient in the biosynthesis of octanoate
could help us answer this question. Alternatively, expressing S. aureus
LipM in an E. coli ΔfabA mutant could conceivably allow us to determine
whether free octanoate can serve as a substrate for LipM in the absence
of endogenous synthesis of octanoic acid.
Importance of LipL in transfer of lipoyl moieties
Previous research revealed that LipL in both B. subtilis and L.
monocytogenes catalyzes the transfer of lipoyl moieties from GcvH to the
E2 subunits of the 2-Oxoacid dehydrogenases (59, 61). Based on this
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information and our results, we are inclined to consider that under normal
conditions, LipL is the central enzyme responsible for transferring the
lipoyl group to all E2 subunits of the 2-Oxoacid dehydrogenases (E2-PDH,
E2-OGDH and E2-BCODH).
We postulate that LplA1, albeit capable of directly lipoylating E2OGDH using free lipoate, has no role in transfer of lipoate among enzyme
complexes. We still need to directly test this hypothesis, but our model is
supported by the data presented in Figure 5, which shows that a ΔgcvH
mutant grown in the absence of supplements is incapable of lipoylation of
E2 subunits. If the lipoate ligase LplA1 were capable of lipoate transfer,
we should observe all three E2 bands in ΔgcvH mutant background, and
that is not reflected in our results.
Of note, in vitro and in vivo research in B. subtilis asserts that LipL
is capable of catalyzing the transfer of both octanoyl and lipoyl moieties
from GcvH to all E2 subunits (54, 61). We cannot arrive to the same
conclusion with the results presented in this thesis, but future research
using purified LipL in lipoylation and octanoylation assays would provide a
definitive assessment.
Lipoate metabolism in regulation and pathogenesis
Upon assessing the organization of lipoate biosynthesis and
salvage genes in the S. aureus genome (Figure 3), we noted that the
genes are dispersed randomly throughout the chromosome. Few
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conclusions could be drawn from this observation, except that the lipoate
biosynthesis and salvage genes are genetically unlinked and may not be
regulated in a concerted manner. From an evolutionary perspective, this
dispersion may also imply that the biosynthesis and salvage genes could
have been acquired through different mechanisms or at different moments
during evolution.
Remarkably, two genes involved in S. aureus lipoate metabolism
appear to have novel genetic linkages; the gene encoding the lipoate
ligase LplA2 belongs to a large operon that contains genes involved in
post-translational modification of protein (52, 53), and the gene for the
lipoyl transferase LipL is located in a putative operon next to the gene that
encodes the S. aureus phosphotransacetylase, Pta (this work).
Information obtained from the literature and our own results suggest that
this genetic arrangement is likely to have a direct impact in regulation of
metabolic processes and possibly redox stress in pathogenesis in S.
aureus (53).
The gene coding for LplA2 is located in a previously identified
operon downstream gcvH-L and next to two genes that encode a
macrodomain protein and a recently discovered sirtuin, SirTM, which has
ADP-ribosyltransferase activity. ADP-ribosylation is a post-translational
modification, often involved in regulation of essential metabolic processes
such as the cell cycle and synthesis and repair (53). Despite not being the
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central focus of their work, Rack et al.. defined for the first time the role of
LplA2 in lipoylating GcvH-L, a non-canonical glycine cleavage system H
protein. Furthermore, their research established that LplA2-dependent
lipoylation is required for the subsequent ADP-ribosyl modification of
GcvH-L (53).
Previous investigation showed that the entire operon was
upregulated under conditions of oxidative stress (53). This information,
along with the known antioxidant properties of lipoate, lead Rack et al. to
propose that the observed crosstalk between lipoylation and ADPribosylation is involved in modulating the response of microbial pathogens
to host-induced oxidative stress (53). In their model, the up-regulation of
GcvH-L lipoylation would serve to increase the availability of lipoate for
anti-redox purposes. Beyond this conclusion, the requirement for
lipoylation prior to ADP-ribosylation of GcvH-L is a central piece of
information, since it also reveals a potential role for protein lipoylation in
the regulation of essential metabolic processes in S. aureus.
The arrangement of lipL in the same operon that pta in the S.
aureus genome could also have important implications in terms of
potential regulation of metabolic processes. Figure 7 describes the
different complementation strategies that we used to achieve restoration
of protein lipoylation and growth of a ΔlipL mutant to WT levels. Strikingly,
successful complementation could only be attained after restoration of the
	
  

90
entire putative operon, suggesting a unique interaction between lipL and
pta.
The pta gene codes for the phosphotransacetylase (Pta), the
enzyme responsible for converting acetyl coenzyme A and phosphate into
the phosphodonor acetyl-phosphate during nutrient-rich growth conditions.
Acetyl-phosphate can be later used to generate ATP and acetate via Ack,
the acetate kinase enzyme (4). Our data suggest that deletion of the LipL
gene may be interfering with the function of Pta, which could potentially
affect the Pta-Ack pathway leading to redirected carbon flux towards
gluconeogenesis, with lactate and pyruvate accumulation (70, 73).
Sadykov et al. showed that a pta mutant had decreased intracellular
levels of acetate and acetyl phosphate and increased levels of acetyl
coenzyme A (70). Inactivation of a lipL pta would additionally block the
pathway to the level of pyruvate, preventing its decarboxylation and
generation of acetyl coenzyme A. When accumulated, this intermediate is
redirected to glucose synthesis or to the TCA cycle (70, 73)
Interestingly, both acetyl coenzyme A and acetyl phosphate seem to
be involved in regulation of metabolic processes in bacteria. In E. coli,
acetyl coenzyme A acts as an acetyl donor to lysine residues during
protein acetylation, and acetyl phosphate has been shown to interact with
two-component signal transduction pathways acting as a phosphoryl
donor (74, 75). This interaction leads to diverse downstream effects, from
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alterations on gene expression and regulation of different cellular
processes, such as organelle generation, biofilm formation, and cell cycle
regulation (74-76).
With this in mind, our observations of a potential interaction
between LipL and Pta suggest a possible role for lipoate in regulation of
the Pta-AckA pathway. Control of the concentrations of acetyl coenzyme A
and acetyl phosphate could influence expression of genes, posttranslational modifications of proteins, and regulation of several virulence
factors, which could have a major impact on S. aureus fitness and
pathogenesis.
If we consider the role of LipL as a lipoyl transferase and the
importance of Pta in S. aureus metabolism and survival, the requirement
for both pta and lipL genes when complementing a ΔlipL mutant is
intriguing. We could speculate that this novel genetic arrangement might
imply a potential role for LipL-dependent protein lipoylation in the
regulation of essential metabolic activities, with an impact on S. aureus
survival in diverse nutritional conditions. Further investigation designed to
study LipL and Pta interactions are currently under investigation in our
laboratory.
The role of lipoate metabolism in S. aureus pathogenesis
Elucidation of the lipoate de novo biosynthesis and salvage pathway
in S. aureus allowed us to investigate the importance of lipoate
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metabolism during infection. We hypothesized that, due to its critical role
in maintaining metabolic flux, lipoate acquisition mechanisms affect S.
aureus pathogenesis. Collectively, the data generated in this work
supports this hypothesis and revealed that the source of lipoate during
sepsis defines infection outcome in the host.
We used a mouse model of sepsis to study the requirement for
lipoate acquisition mechanisms in vivo, and measured bacterial burden in
tissues of mice infected with different mutant strains. The evaluation of
the requirement for de novo biosynthesis of lipoate during sepsis showed
that the endogenous lipoylation of proteins is required for S. aureus
infection of the heart in mice. In contrast, S. aureus replication in the
kidneys required the action of the lipoate ligases, but not lipoate
biosynthesis functions (Figure 8).
The individual contribution of the lipoate ligases LplA1 and LplA2 to
pathogenesis in vivo was determined by comparing the infection capacity of the
single deletion mutant strains to ΔlplA1 ΔlplA2 double mutant complemented with
either lplA1 or lplA2 in mice (Figure 12). This study allowed us to conclude that
efficient seeding of S. aureus of the kidneys relies upon the activity the lipoate
ligases. This was confirmed by the experiments conducted on ΔlipA ΔlplA1
ΔlplA2 complemented with either lpla1 or lpla2 (Figure 14), demonstrating that
both lipoate ligases, LplA1 and LplA2, could restore wild type infection
phenotype.
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Our observations differ from the role reported for L. monocytogenes LplA1
and LplA2, which exhibited a robust salvage activity in vitro. However, while L.
monocytogenes LplA1 is dispensable for growth in medium containing lipoate, is
required for intracellular replication and virulence (15, 19, 61). In contrast, S.
aureus LplA2 cannot ligate lipoate in vitro under the conditions tested during this
work, yet either lipoate ligases is sufficient to infect the host, indicating that LplA2
is capable of lipoylating proteins in the host. A possible experiment to test the
role of LplA2 in protein lipoylation in vivo could be done by isolating colonies from
absences in the hearts and kidneys after infection with ΔlipA ΔlplA1 ΔlplA2 +
lplA2, and evaluating the presence of lipoylated proteins via mass spectroscopy.
Remarkably, we were able to demonstrate in vitro lipoylation activity
for LplA2 only after introduction of a complementation construct in the
triple mutant ΔlipA ΔlplA1 ΔlplA2, in which the P HELP promoter
constitutively drives the expression of lplA2. Although we could not detect
a role in salvage of lipoate during broth culture, lplA2 expression was
sufficient to promote sepsis in vivo to levels equivalent to that of LplA1,
suggesting that this gene could be upregulated in the host. This was
observed after comparing infectivity in mice of the single deletion mutants
ΔlplA1 and ΔlplA1 to the double mutant ΔlplA1 ΔlplA2 followed by
complementation with lplA1 or lplA2 (Figure 12). Another possible
explanation for this result, besides a potential upregulation of lplA2
expression, is that the induction of tissue damage in the host lead to an
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increase on the availability of different lipoylated substrates preferred by
LplA2 in vivo that were not supplied in broth culture. In other words, LplA2
might have alternative preferred substrates, such as peptide-bound
lipoate, instead of free lipoate. Conceivably, LplA2 could be interacting
with a lipoamidase in vivo or have lipoamidase activity itself, which would
facilitate the release of lipoate moieties from proteins and peptides
available in vivo. An alternative explanation could be that LplA2 only
functions to lipoylate GcvH-L, and, as mentioned above, the operon that
contains the pair LplA2/GcvH-L is active in vivo and not in vitro (70, 73).
Regardless of the mechanism by which LplA2 is functioning in vivo,
it is remarkable that S. aureus has the ability to use two lipoate ligases to
scavenge this essential cofactor during infection. This is a novel feature of
lipoate acquisition in pathogenic bacteria and most likely facilitates S.
aureus adaptation to nutrient-limited environments during infection.
Additionally, it is known that lipoate is a potent antioxidant compound and
the efficient scavenging of this cofactor from tissues could constitute a
strategy aimed to counter the oxidative stress response induced by the
host during infection (11, 12, 16, 53).
Consistent with our in vitro findings, the assessment of the triple
mutant ΔlipAΔlplA1ΔlplA2 in vivo established that S. aureus relies on
lipoate acquisition for pathogenesis. In other words, S. aureus is
incapable of using other metabolic strategies, such as anaerobic
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metabolism, to infect the host. In sum, our data revealed that bacterialgenerated lipoate is required for infection in the heart, but host-derived
lipoate is necessary to infect the kidneys.
The reason for the striking division of labor among enzymes
involved in lipoate salvage is currently unknown, but not uncommon in
nature. A few malarial parasites showed organelle-specific acquisition of
lipoate, with lipoate biosynthesis supplying this cofactor in the apicoplast,
and environmentally acquired lipoate used in the mitochondrion (14, 18,
62). Additionally, the malarial parasite P. falciparum has two lipoate
ligases, pfLplA1 and pfLplA2 that reside differentially in those organelles;
pfLplA is located the mitochondrion, the site for lipoate de novo
biosynthesis and the organelle in which PDH is synthetized. In contrast,
pfLplA2 can be found in the mitochondrion as well as in the apicoplast, in
which GcvH and BCDH are lipoylated.
Finally, differences in lipoate concentration or lipoate sources
between the heart and the kidney could potentially explain these
observations. In fact, Akiba et al. showed that albeit the levels of free
lipoate are generally low in all mammal tissues the kidneys had the
highest content of total lipoate compared to other tissues (49).
Unfortunately, we lack more precise information on lipoylated substrate
availability in mammalian tissues in order to draw firm conclusions on
substrate accessibility. Likewise, we lack information on the ability of S.
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aureus to incorporate protein/peptide-bound lipoate from infectious
sources. Future directions aimed at shedding light on these remaining
problems, include: (1) Characterize the preferred sources of lipoate used
by the enzymes involved in lipoate de novo biosynthesis and salvage; (2)
conduct enzymatic assays to determine the affinity for different lipoylated
substrates and; (3) evaluate the expression of the enzymes involved in
lipoate acquisition both in vitro and in vivo. Together, these future studies
will clarify the mechanisms used by S. aureus to promote optimal
replication in the host and might help identify potential drug targets to fight
S. aureus infections.
Final remarks
In this thesis, we have proposed a model for the de novo
biosynthesis and salvage pathway of lipoate in Staphylococcus aureus
and demonstrated the critical role of lipoate acquisition in S. aureus
pathogenesis. Furthermore, we have identified a previously overlooked
genetic arrangement of lipoate de novo biosynthesis and salvage genes in
the S. aureus genome that suggests a potential role for protein lipoylation
in the regulation of key metabolic processes and defense mechanisms
against host oxidative burst. We have also established the biological
function of each gene product involved in lipoate metabolism and
determined the contribution of the lipoate acquisition mechanisms to S.
aureus infection. As a result, we propose that S. aureus is capable of
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utilizing bacterial and host-derived lipoate during infection in a tissuespecific manner, thereby promoting survival in a wide variety of nutrientrestricted environments. The significant defects in virulence seen after
blocking de novo biosynthesis and salvage of lipoic acid during sepsis
offer potential for the development of novel therapeutics that target lipoate
de novo biosynthesis and salvage enzymes in the treatment of S. aureus
infection.
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APPENDIX II

SUPPLEMENTARY FIGURES

Figure 17: Growth curves of mutant sets in RPMI BCFA
Growth curves in RPMI BCFA of the indicated mutant strains sets: A) Single deletion mutants
(ref. Fig. 5), B) Double deletion strains constructed in the background of a lipA deletion mutant
(ref. Fig. 8), C) Double deletion strains constructed in the background of a lipM deletion mutant
(ref. Fig. 10) D), Triple deletion strains of the de novo biosynthesis and salvage pathway enzymes
(ref. Fig. 9).
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Figure 18: LipM lipoylation profile
LipM is capable of protein lipoylation to E2-OGDH. Immunoblots of whole cell lysates of the
indicated mutant strains grown in RPMI + BCFA + Octanoate, detected with anti-lipoic acid
antibody (C). This experiment was performed as previously described but the amount of sample
loaded in each well was increased by a 1.5 factor.
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Figure 19: Whole cell protein patterns I
Proteins from whole cell lysates were resolved in 12% polyacrylamide gels and stained using
GelCode Blue stain reagent (Thermo). The molecular weight of the proteins was marked using
Precision Plus Protein Ladder™ (Thermo). The rows organize samples grown in

RPMI+BCFA media (BCFA), RPMI+lipoate (+LA) or RPMI+octanoate (+OA). Columns
organize the set of mutants tested: the first column depicts the protein patterns of the set
of mutants used in figure 6. The column at the center reflects the protein patterns of
mutants used for figure 9. Protein patterns of mutant strains tested in figure 11 are
shown on the left column.
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Figure 20: Whole cell protein patterns II
Proteins from whole cell lysates were resolved in 12% polyacrylamide gels and stained using
GelCode Blue stain reagent (Thermo). The molecular weight of the proteins was marked using
Precision Plus Protein Ladder™ (Thermo). The rows organize samples grown in

RPMI+BCFA media (BCFA), RPMI+lipoate (+LA) or RPMI+octanoate (+OA). The right
column depicts the protein patterns of the set of mutants used in figure 13. The protein
patterns shown on the left belong to the mutant strains used in figure 10.
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